Home | Curriculum Vitae | Curriculum Vitae Abbreviated  | Biography | Lab Notes | Clinical Research
 

 

Curriculum Vitae

Nicholas Bruchovsky, Vancouver, B.C.

Present address
 

1736 West 37th Avenue
Vancouver, British Columbia
Canada V6M 1N1

     
Place of birth   Canada
     
Degrees obtained  
  • MD, Faculty of Medicine, University of Toronto, 1961.
  • PhD, Department of Medical Biophysics, University of Toronto, 1966.
  • FRCPC, Royal College of Physicians and Surgeons of Canada, 1975.
Positions held  
  • Rotating Intern, Toronto General Hospital, Toronto, Ontario, 1961 - 1962.
  • Fellow, Department of Internal Medicine, Southwestern Medical School, Dallas, Texas, 1966 - 1968.
  • Resident, Department of Internal Medicine, Parkland Memorial Hospital, Dallas, Texas, 1966 - 1968.
  • Assistant Professor of Medicine, University of Alberta, Edmonton, Alberta, 1969 - 1970.
  • Associate Professor of Medicine, University of Alberta, Edmonton, Alberta, 1970 - 1976.
  • Professor of Medicine, University of Alberta, Edmonton, Alberta, 1976 - 1979.
  • Head, Genitourinary Endocrine Clinic, British Columbia Cancer Agency, Vancouver Clinic, 1983 - 1992.
  • Professor of Medicine, University of British Columbia, Vancouver, British Columbia, 1979 - 2001.
  • Head, Division of Cancer Endocrinology, BC Cancer Agency, Vancouver, British Columbia, 1979 - 2001.
  • Medical Oncology Consultant, University of British Columbia Prostate Clinic, Vancouver Hospital, 1993 - 2001.
  • Clinical Professor, Department of Urology, School of Medicine, University of Washington, Seattle, Washington, 1993 - present.
  • Honorary Professor of Medicine, University of British Columbia, Vancouver, British Columbia, 2001 - present.
  • Emeritus Clinician-Scientist, The Vancouver Prostate Centre, Vancouver, British Columbia, 2001 - present.
  • Medical Advisory Board, Prostate Cancer Research Institute, Los Angeles, California, 2002 - present.
Hospital affiliations  
  • University of Alberta Hospital, Active Staff 1969-1979.
  • British Columbia Cancer Agency, Vancouver Clinic, Active Staff 1979 - 2001.
  • Vancouver General Hospital, Active Staff 1980 - 2001.
  • Vancouver General Hospital, Honorary Staff 2002 - present.
Professional and scientific societies  
  • American Society for Basic Urologic Research
  • Canadian Association of Medical Oncologists
  • Canadian Oncology Society
  • Canadian Society for Clinical Investigation
  • Canadian Society for Endocrinology and Metabolism
  • Canadian Urologic Oncology Group
  • College of Physicians and Surgeons of British Columbia
  • Royal College of Physicians and Surgeons of Canada
  • The Endocrine Society, USA
Editorial boards  
  • The Prostate, 1980 - 2001.
  • Endocrine-Related Cancer, 1993 - 2001.
Awards  
  • Fellowship, National Cancer Institute of Canada, 1963 - 1966.
  • Scholarship, Medical Research Council of Canada, 1970 - 1975.
  • Distinguished Faculty of Medicine Research Lecture University of British Columbia, 1991.
  • D.R. Edwards Memorial Lecture and Medal, University of Wales College of Medicine, 1993.
  • The 30th John W. Whittick Memorial Lecture, Canadian Cancer Society, Saskatchewan Division, 1993.
  • The Bodo von Garrelts Lecture, Karolinska Institute, Sweden, 1997.
  • Terry Fox Medal for outstanding contribution to cancer medicine, British Columbia Medical Association, 2001.
  • The Commemorative Medal for the Golden Jubilee of Her Majesty Queen Elizabeth II, for outstanding contribution to medicine and the medical profession, 2003.
  • University of Toronto , Sports Hall of Fame (Football), 2007.
  • The Straith Trophy, in recognition of excellence benefiting men with prostate cancer, 2008.
  • Society for Basic Urologic Research (U.S.A), Meritorious Achievement Award for dedication and contributions to the field of Basic Urologic Research, 2011.
Research  
  • The major ongoing projects that continue to be my focus in retirement is the clinical evaluation of intermittent androgen suppression in the treatment of prostate cancer and the development of mathematical models as related to such therapy.

Publications

1. BRUCHOVSKY, N., OWEN, A.A., BECKER, A.J. and TILL, J.E.:
Effects of vinblastine on the proliferative capacity of L cells and their progress through the division cycle.  Cancer Res  25:1232-1237 (1965).
2. BRUCHOVSKY, N. and TILL, J.E.:
Effects of β-phenethyl alcohol in mouse L cells in suspension culture. I. Reversible inhibition of cell proliferation and effects on the uptake of labeled precursors of nucleic acid and protein.  Mol Pharmacol  3:124-132 (1967).
3. BRUCHOVSKY, N., MAK, S. and TILL, J.E.:
Effects of -phenethyl alcohol on mouse L cells in suspension culture. II. Effects on the cell division cycle.  Mol Pharmacol  3:133-141 (1967).
4. BRUCHOVSKY, N. and WILSON, J.D.:
The conversion of testosterone to 5α-androstan-17β-ol-3-one by rat prostate in vivo and in vitro.  J Biol Chem  243:2012-2021 (1968). Citation Classic: Current Contents, Vol. 23, No. 30, July 28, 1980.
5. BRUCHOVSKY, N. and WILSON, J.D.:
The intranuclear binding of testosterone and 5α-androstan-17β-ol-3-one by rat prostate.  J Biol Chem  243:5953-5960 (1968).
6. WILSON, J.D., BRUCHOVSKY, N. and CHATFIELD, J.N.:
Intranuclear localization of testosterone-1, 2-3H in rat prostate.  Progr Endocrinol  17-23 (1969).
7. BRUCHOVSKY, N.:
Comparison of the metabolites formed in rat prostate following the in vivo administration of seven natural androgens.  Endocrinol  89:1212-1222 (1971).
8. RENNIE, P.S. and BRUCHOVSKY, N.:
In vitro and in vivo studies on the functional significance of androgen receptors in rat prostate.  J Biol Chem  247:1546-1554 (1972).
9. BRUCHOVSKY, N.:
The metabolism of testosterone and dihydrotestosterone in an androgen-dependent tumour.  Biochem J  127:561-575 (1972).
10. RENNIE, P.S. and BRUCHOVSKY, N.:
Studies on the relationship between androgen receptors and the transport of androgens in rat prostate.  J Biol Chem  248:3288-3297 (1973).
11. LESSER, B. and BRUCHOVSKY, N.:
The effects of testosterone, 5α-dihydrotestosterone and adenosine 3', 5' - monophosphate on cell proliferation and differentiation in rat prostate.  Biochem Biophys Acta  308:426-437 (1973).
12. BRUCHOVSKY, N. and MEAKIN, J.W.:
The metabolism and binding of testosterone in androgen-dependent and autonomous transplantable mouse mammary tumors.  Cancer Res  33:1689-1695 (1973).
13. LESSER, B. and BRUCHOVSKY, N.:
Effect of duration of the period after castration on the response of the rat ventral prostate to androgens.  Biochem J  149:429-431 (1974).
14. LESSER, B. and BRUCHOVSKY, N.
The effects of 5α-dihydrotestosterone on the kinetics of cell proliferation in rat prostate.  Biochem J  142:483-489 (1974).
15. CRAVEN, S., LESSER, B. and BRUCHOVSKY, N.:
Evidence that adenosine 3':5' - cyclic monophosphate is not involved in the growth response of prostate to androgens.  Endocrinology  95(4):1177-1180 (1974).
16. BRUCHOVSKY, N., SUTHERLAND, D.J.A., MEAKIN, J.W. and MINESITA, T.:
Androgen receptors: relationship to growth response and to intracellular androgen transport in nine variant lines of the Shionogi mouse mammary carcinoma.  Biochem Biophys Acta  381:61-71 (1975).
17. BRUCHOVSKY, N. and CRAVEN, S.:
Prostatic involution: Effect on androgen receptors and intracellular androgen transport.  Biochem Biophys Res Comm  62:837-843 (1975).
18. BRUCHOVSKY, N., RENNIE, P.S. and VANSON, A.:
Studies on the regulation of the concentration of androgens and androgen receptors in nuclei of prostatic cells.  Biochem Biophys Acta  394:248-266 (1975).
19. BRUCHOVSKY, N., RENNIE, P.S., LESSER, B. and SUTHERLAND, D.J.A.:
The influence of androgen receptors on the concentration of androgens in nuclei of hormone - responsive cells.  J Steroid Biochem  6:551-560 (1975).
20. BRUCHOVSKY, N., LESSER, B. and RENNIE, P.S.:
Control of the concentration and distribution of dihydrotestosterone in prostatic cells. In "Normal and Abnormal Growth of the Prostate", (Goland, M., ed).  Charles C. Thomas, Springfield  pp. 125-143 (1975).
21. BRUCHOVSKY, N., LESSER, B., VAN DOORN, E. and CRAVEN, S.:
Hormonal effects on cell proliferation in rat prostate.  Vitam Horm  33:61-102 (1975). Article abstract published in Yearbook of Cancer 1977.
22. BRUCHOVSKY, N. and LESSER, B.:
Control of proliferative growth in androgen responsive organs and neoplasms.  Adv Sex Horm Res  2:1-55 (1976).
23. VAN DOORN, E., CRAVEN, S. and BRUCHOVSKY, N.:
The relationship between androgen receptors and the hormonally controlled responses of rat ventral prostate.  Biochem J  160:11-21 (1976).
24. BRUCHOVSKY, N., RENNIE, P.S. and VAN DOORN, E.J.:
Steroid receptors in cancer.  Mod Med Can  31:914-918 (1976).
25. BRUCHOVSKY, N. and VAN DOORN, E.:
Steroid receptor proteins and regulation of growth in mammary tumours.  Recent Results Cancer Res  57:121-142 (1976). Article abstract published in Yearbook of Cancer 1978.
26. BRUCHOVSKY, N. and VAN DOORN, E.:
Receptor proteins in tumours and hormonal responses.  Res Steroids  7:225-251 (1977).
27. RENNIE, P.S., VAN DOORN, E. and BRUCHOVSKY, N.:
Methods for estimating the concentration of different forms of androgen receptor in rat ventral prostate.  Mol Cell Endocrinol  9:145-157 (1977).
28. BRUCHOVSKY, N., RENNIE, P.S. and VAN DOORN, E.J.:
Estrogen receptors - can they predict tumor response to hormone therapy.  Mod Med USA  46:64-74 (1978).
29. BRUCHOVSKY, N. and RENNIE, P.S.:
Classification of dependent and autonomous variants of Shionogi mammary carcinoma based on heterogeneous patterns of androgen binding.  Cell  13:273-280 (1978).
30. VAN DOORN, E. and BRUCHOVSKY, N.:
Mechanisms of replenishment of nuclear androgen receptor in rat ventral prostate.  Biochem J  174:9-16 (1978).
31. BRUCHOVSKY, N., RENNIE, P.S., VAN DOORN, E. and NOBLE, R.L.:
Pathological growth of androgen sensitive tissues resulting from latent actions of steroid hormones.  J Toxicol Environ Health  4:391-408 (1978).
32. RENNIE, P.S., BRUCHOVSKY, N. and HOOK, S.L.:
Androgenic regulation of a tissue specific isoenzyme of acid phosphatase in rat ventral prostate.  J Steroid Biochem  9:585-593 (1978).
33. LIESKOVSKY, G. and BRUCHOVSKY, N.:
Assay of nuclear androgen receptor in human prostate.  J Urol  121:54-58 (1979).
34. BRUCHOVSKY, N. and LIESKOVSKY, G.:
Increased ratio of 5α-reductase: 3α(β)-hydroxysteroid dehydrogenase activities in the hyperplastic human prostate.  J Endocrinol  80:289-301 (1979).
35. BRUCHOVSKY, N. and RENNIE, P.S.:
Steroid receptors and the regulation of DNA synthesis.  UICC Tech Rep Ser  48:134-144 (1979).
36. BRUCHOVSKY, N. and RENNIE, P.S.:
New considerations in the hormonal induction and regulation of animal tumors.  UICC Tech Rep Ser  48:220-232 (1979).
37. BRUCHOVSKY, N.:
Molekulare wirkung von androgenen und antiandrogenen. In "Androgenisierungserscheinungen bei der Frau", (Hamerstein, J., Lachnit-Fixon, U., Neumann, F. and Plewig, G., eds.).  Excerpta Medica Amsterdam  pp. 7-21 (1979).
38. BRUCHOVSKY, N., RENNIE, P.S. and WILKIN, R.P.:
New aspects of androgen action in the prostatic cells: stromal localization of 5α-reductase, nuclear abundance of androstanolone and binding of receptor to linker deoxyribonucleic acid. In "Steroid Receptors, Metabolism and Prostatic Cancer", (Schroeder, F.H. and de Voogt, H.J., eds.).  Excerpta Medica Amsterdam  pp. 57-76 (1979).
39. BRUCHOVSKY, N., CALLAWAY, T., LIESKOVSKY, G. and RENNIE, P.S.:
Markers of androgen action in human prostate: potential use in the clinical assessment of prostatic carcinoma. In "Steroid Receptors and Hormone-Dependent Neoplasia" (Wittliff, J.L. and Dapunt, O., eds.).  Masson Publishing, New York  pp. 121-131 (1980).
40. RENNIE, P.S. and BRUCHOVSKY, N.:
Measurement of androgen receptors. In "Male Accessory Sex Glands", Human Reproductive Medicine, Vol. 4. (Spring-Mills, E. and Hafez, E.S.E., eds.).  Elsevier/North-Holland Biomedical Press, Amsterdam  pp. 265-287 (1980).
41. WILKIN, R.P., BRUCHOVSKY, N., SHNITKA, T.K., RENNIE, P.S. and COMEAU, T.L.:
Stromal 5α-reductase activity is elevated in benign prostatic hyperplasia.  Acta Endocrinol  94:284-288 (1980).
42. BRUCHOVSKY, N., RENNIE, P.S. and SHNITKA, T.K.:
Cellular factors contributing to the high concentration of dihydrotestosterone in hyperplastic and carcinomatous human prostates. In "Hormones and Cancer", Progress in Cancer Research and Therapy, Vol 14, (Iacobelli, S., King, R.J.B., Lindner, H.R. and Lippman, M.E., eds.).  Raven Press, New York  pp. 457-470 (1980).
43. RENNIE, P.S., BRUCHOVSKY, N., NOBLE, R.L. and MO, S.:
Nuclear binding of androgens and acid phosphatase activity in prostatic tumors of Nb rats.  Biochem Biophys Acta  632:428-436 (1980).
44. RENNIE, P.S., BRUCHOVSKY, N., NOBLE, R.L. and MO, S.:
Plasminogen activator in prostatic tumors of Nb rats.  Biochem Biophys Acta  632:437-443 (1980).
45. RENNIE, P.S. and BRUCHOVSKY, N.:
Hormone receptors in prostatic tissue.  Res Steroids  9:120-125 (1980).
46. BRUCHOVSKY, N.:
The control of neoplastic growth by alterations in hormonal balance. In "Readings in Oncology", (Day, S.B., Sugarbaker, E.V., Rosch, P.J. and Warren, B.A., eds.).  International Foundation for Biosocial Development and Human Health, New York  pp. 37-43 (1980).
47. GOLDIE, J.H., BRUCHOVSKY, N., COLDMAN, A.J. and GUDAUSKAS, G.:
Steroid receptors in the adjuvant hormonal therapy of breast cancer.  Can J Surg  24:290-293 (1981).
48. De LARMINAT, M.A., RENNIE, P.S. and BRUCHOVSKY, N.:
Radioimmunoassay measurements of nuclear dihydrotestosterone in rat prostate: relationship to androgen receptors and androgen-regulated responses.  Biochem J  200:465-474 (1981).
49. BRUCHOVSKY, N., RENNIE, P.S. and COMEAU, T.:
Partial purification of nuclear androgen receptor by micrococcal nuclease digestion of chromatin and hydrophobic interaction chromatography.  Eur J Biochem  120:399-405 (1981).
50. FILIPENKO, J.D., RENNIE, P.S. and BRUCHOVSKY, N.:
The androgenic regulation of superhelical-DNA nicking-closing enzyme in rat ventral prostate.  Biochem J  196:195-202 (1981).
51. BRUCHOVSKY, N., McLOUGHLIN, M.G., RENNIE, P.S. and TO, M.:
Partial characterization of stromal and epithelial forms of 5α-reductase in human prostate. In "The Prostate Cell: Structure & Function", Part A, (Murphy, G.P., Sandberg, A.A. and Karr, J.P., eds.).  Alan R. Liss Inc., New York  pp. 161-175 (1981).
52. BRUCHOVSKY, N.:
Rationale for the use of steroid receptors in the adjuvant hormonal therapy of breast cancer.  Rev Endocrine-Related Cancer  7:Suppl:21-26 (1981).
53. De LARMINAT, M.A., BRUCHOVSKY, N. and RENNIE, P.S.:
Concentration and preservation of nuclear androgen receptor by lyophilisation.  J Steroid Biochem  16:811-816 (1982).
54. RENNIE, P.S., BRUCHOVSKY, N., MO., S., DE JONG, G. and CHENG, H.:
Plasminogen activator activity in human prostate and breast tumors: relationship to steroid receptors.  The Prostate  3:483-492 (1982).
55. CALLAWAY, T.W., BRUCHOVSKY, N., RENNIE, P.S. and COMEAU, T.:
Mechanisms of action of androgens and anti-androgens: effects of anti-androgens on translocation of cytoplasmic androgen receptor and nuclear abundance of dihydrotestosterone.  The Prostate  3:599-610 (1982).
56. (Book) BRUCHOVSKY, N. and GOLDIE, J.H. (eds):
Drug and Hormone Resistance in Neoplasia, Volume 1, Basic Concepts.  CRC Press, Boca Raton  (1982).
57. McLOUGHLIN, M.G. and BRUCHOVSKY, N.:
Stromal-epithelial interaction. In "Benign Prostatic Hypertrophy", (Hinmann, F., Jr., ed.).  Springer-Verlag, New York  pp. 130-140 (1983).
58. BRUCHOVSKY, N.:
Rationale for the use of anti-hormone and drug combinations in the treatment of prostatic carcinoma. In "Androgens and Anti-androgens", (Schroeder, F.H., ed.).  Schering Nederland BV, Weesp  pp. 35-51 (1983).
59. GOLDIE, J.H., COLDMAN, A.J. and BRUCHOVSKY, N.:
A quantitative model for drug resistance in cancer chemotherapy. In "Rationale Basis for Chemotherapy", (Chabner, B.A., ed.).  Alan R. Liss Inc., New York  pp. 23-39 (1983).
60. RENNIE, P.S., BRUCHOVSKY, N., McLOUGHLIN, M.G., BATZOLD, F.H. and DUNSTAN-ADAMS, E.E.:
Kinetic analysis of 5α-reductase isoenzymes in benign prostatic hyperplasia (BPH).  J Steroid Biochem  19:169-173 (1983).
61. RENNIE, P.S., BRUCHOVSKY, N. and CHENG, H.:
Isolation of 3s androgen-receptors from salt-resistant fractions and nuclear matrices of prostatic nuclei after mild trypsin digestion.  J Biol Chem  258:7623-7630 (1983).
62. DJOSELAND, O., BRUCHOVSKY, N., RENNIE, P.S., OTAL, N. and HOGLO, S.:
5α-reductase activity in stroma and epithelium of rat prostate and epididymis. A contribution to elucidation of the mechanism for development of hyperplastic growth of prostatic tissue.  Acta Endocrinol  103:273-281 (1983).
63. (Book) BRUCHOVSKY, N. and GOLDIE, J.H. (eds.):
Drug and Hormone Resistance in Neoplasia, Volume II, Clinical Concepts.  CRC Press, Boca Raton  (1983).
64. BRUCHOVSKY, N. and GOLDIE, J.H.:
Basis for the use of drug and hormone combinations in the treatment of endocrine-related cancer. In "Drug and Hormone Resistance in Neoplasia, Volume II, Clinical Concepts", (Bruchovsky, N. and Goldie, J.H., eds.).  CRC Press, Boca Raton  pp. 129-162 (1983).
65. RENNIE, P.S., BRUCHOVSKY, N., CHENG, H. and FOEKENS, J.A.:
Turnover of 3s androgen receptors bound to the nuclear matrix of prostatic nuclei. In "Hormones and Cancer 2", Progress in Cancer Research and Therapy, Vol. 31, (Bresciani, F., King, R.J.B., Lippman, M.E., Namer, M. and Raynaud, J.P., eds.).  Raven Press, New York  pp. 73-77, (1984).
66. DeLARMINAT, M.A., BRUCHOVSKY, N., RENNIE, P.S., LEE, S.P. and TERTZAKIAN, G.:
Synthesis and evaluation of immobilized androgens for affinity chromatography in the purification of nuclear androgen receptor.  The Prostate  5:123-140 (1984).
67. DeLARMINAT, M.A., SCORTICATI, C., RENNIE, P.S. and BRUCHOVSKY, N.:
Androgen receptor assay in small biopsies of human prostate. Preservation of nuclear receptor from rat ventral prostate by lyophilization.  Progr Clin Biol Res  142:261-290 (1984).
68. GOUT, P.W., TZE, W.J., RENNIE, P.S. and BRUCHOVSKY, N.:
Bioassay and radioimmunoassay of the lactogens in sera from children.  Clin Chem Acta  139:23-27 (1984).
69. RENNIE, P.S., BOUFFARD, R., BRUCHOVSKY, N. and CHENG, H.:
Increased activity of plasminogen activators during involution of the rat ventral prostate.  Biochem J  221:171-178 (1984).
70. GOUT, P.W., NOBLE, R.L., BRUCHOVSKY, N. and BEER, C.T.:
Vinblastine and vincristine - growth-inhibitory effects correlate with their retention by cultured Nb2 node lymphoma cells.  Int J Cancer  34:245-248 (1984).
71. EMERMAN, J.T., LEAHY, M., GOUT, P.W. and BRUCHOVSKY,N.:
Elevated growth hormone and prolactin levels in sera from breast cancer patients determined by radioimmunoassay and bioassay.  Horm Metab Res  17:421-424 (1985).
72. RENNIE, P.S., PRIOR, J.C., BRUCHOVSKY, N. and GOUT, P.W.:
Bioactive forms of serum lactogens: Effects of treatment of prolactinoma patients with bromocriptine.  Clin Endocrinol  22:65-73 (1985).
73. BRUCHOVSKY, N., RENNIE, P.S., OTAL, N., GILES, M.G., PONTIFEX, H. and VANSON, A.:
Variability of androgen-related phenotypes in the Shionogi carcinoma during growth involution, recurrence and progression to hormonal resistance.  Cancer Res  45:682-689 (1985).
74. (Book) BRUCHOVSKY, N., CHAPDELAINE, A. and NEUMANN, F. (eds.):
Regulation of Androgen Action.  Congressdruck R. Bruckner, Berlin  (1985).
75. BRUCHOVSKY, N. and DUNSTAN-ADAMS, E.:
Regulation of 5α-reductase activity in stroma and epithelium of human prostate. In "Regulation of Androgen Action", (Bruchovsky, N., Chapdelaine, A. and Neumann, F., eds.).  Congressdruck R. Bruckner, Berlin  pp. 31-35 (1985).
76. FOEKENS, J.A., RENNIE, P.S., CHENG, H. and BRUCHOVSKY, N.:
In situ cross-linking of androgen receptors to nuclear acceptor sites of rat prostate with formaldehyde.  J Biol Chem  260:10093-10098 (1985).
77. GILES, M.G., RENNIE, P.S. and BRUCHOVSKY, N.:
Changes in endonuclease activity during growth and regression of the Shionogi mammary carcinoma.  Mol Cell Endocrinol  45:167-173 (1986).
78. BRUCHOVSKY, N.:
This week's citation classic. In "Contemporary Classics in the Life Sciences, Volume 2: The molecules of life", (Barrett, J.T., ed.)  iSi Press, Philadelphia  p. 183 (1986).
79. BRUCHOVSKY, N., RENNIE, P.S., GOUT, P.W. and GOLDENBERG, S.L.:
Endocrinology of tumour progression. In "Endocrine-related Tumours", (Engelsman, E. and de Koning Gans, H.J., eds.).  Update-Siebert Publications Ltd, Guildford  pp. 9-26 (1987).
80. GOLDENBERG, S.L., BRUCHOVSKY, N., RENNIE, P.S., COPPIN, C.M.L. and BROWN, E.M.:
The use of synergistic hormonal combinations in the treatment of advanced prostatic cancer: cyproterone acetate plus mini-dose diethylstilbestrol. In "Hormonal Manipulation of Cancer: Peptides, Growth Factors and New (Anti) Steroidal Agents", (Klijn, J.G.M., Paridaens, R. and Foekens, J.A., eds.).  Raven Press, New York  pp. 127-133 (1987).
81. BRUCHOVSKY, N., RENNIE, P.S., TO, M.P., SNOEK, R., LEFEBVRE, Y.A. and GOLSTEYN, E.J.:
Chemical demonstration of nuclear androgen receptor following affinity chromatography with immobilized ligands.  The Prostate  10:207-222 (1987).
82. RENNIE, P.S., BOWDEN, J.F., BRUCHOVSKY, N., FRENETTE, P.S., FOEKENS, J.A. and CHENG, H.:
DNA and protein components of nuclear acceptor sites for androgen receptors in the rat prostate.  J Steroid Biochem  27:513-520 (1987).
83. (Book) COFFEY, D.S., BRUCHOVSKY, N., GARDNER, W.A. Jr., RESNICK, M.I. and KARR, J.P. (eds.):
Current Concepts and Approaches to the Study of Prostate Cancer.  Alan R. Liss Inc., New York  (1987).
84. BRUCHOVSKY, N., BROWN, E.M., COPPIN, C.M., GOLDENBERG, S.L., LE RICHE, J.C., MURRAY, N.C. and RENNIE. P.S.:
The endocrinology and treatment of prostate tumor progression. In "Current Concepts and Approaches to the Study of Prostate Cancer", (Coffey, D.S., Bruchovsky, N., Gardner, W.A. Jr., Resnick, M.I. and Karr, J.P., eds.).  Alan R. Liss Inc., New York  pp. 347-387 (1987).
85. GOUT, P.W., BEER, C.T., DE JONG, G., RENNIE, P.S. and BRUCHOVSKY, N.:
Prolactin-induced generation of transferring receptors: a critical event in the mitogenesis of lactogen-dependent Nb2 node rat lymphoma cells. In "Hormones and Cancer 3", Progress in Cancer Research and Therapy, Vol. 35 (Bresciani, F., Lippman, M.E., King, R.J.B. and Raynaud, J.P., eds.).  Raven Press, New York  pp. 242-249 (1987).
86. RENNIE, P.S., BRUCHOVSKY, N. and GOLDENBERG, S.L.:
Relationship of androgen receptors to the growth and regression of the prostate.  Amer J Clin Oncol  11:513-517 (1988).
87. BRUCHOVSKY, N., RENNIE, P.S. and GOLDENBERG, S.L.:
Mechanisms and effects of androgen withdrawal therapies. In "Prostate Cancer: Rationale of Endocrine Management".  Walter De Gruyter & Co., Berlin  pp. 3-14, (1988).
88. RENNIE, P.S., BOWDEN, J.F., BRUCHOVSKY, N. and CHENG, H.:
The relationship between inhibition of plasminogen activator activity and prostatic involution.  Biochem J  252:759-764 (1988).
89. RENNIE, P.S., BRUCHOVSKY, N., GOLDENBERG, S.L., LAWSON, D., FLETCHER, T. and FOEKENS, J.A.:
Relative effectiveness of alternative androgen withdrawal therapies in initiating regression of rat prostate.  J Urol  139:1337-1342 (1988).
90. (Discussion) BRUCHOVSKY, N.:
Hormonal Treatment Approaches to D2 disease. In "A Multidisciplinary Analysis of Controversies in the Management of Prostate Cancer", (Coffey, D.S., Resnick, M.I., Dorr, F.A. and Karr, J.P., eds.).  Alan R. Liss, Inc., New York  pp. 245-259 (1988).
91. BRUCHOVSKY, N., RENNIE, P.S., BATZOLD, F.H., GOLDENBERG, S.L., FLETCHER, T. and McLOUGHLIN, M.G.:
Kinetic parameters of 5α-reductase activity in stroma and epithelium of normal, hyperplastic and carcinomatous human prostates.  J Clin Endocrinol Metab  67:806-816 (1988).
92. GOLDENBERG, S.L., BRUCHOVSKY, N., RENNIE, P.S. and COPPIN, C.M.L.:
The combination of cyproterone acetate and low-dose diethylstilbestrol in the treatment of advanced prostatic carcinoma.  J Urol  140:1460-1465 (1988). Article abstract published in Yearbook of Drug Therapy 1990.
93. RENNIE, P.S., BRUCHOVSKY, N., BUTTYAN, R. and CHENG, H.:
Gene expression during the early phases of regression of the androgen-dependent Shionogi mouse mammary carcinoma.  Cancer Res  48:6309-6312 (1988).
94. LE RICHE, J.C., BRUCHOVSKY, N., GOLDENBERG, S.L. and de JONG, G.:
Flow cytometry in the cytological and clinical assessment of prostatic carcinoma. In "Cytopathology/Flow Cytometry and Prognostic Indicators of Prostate Cancer", (Karr, J.P., Coffey, D.S. and Gardner, W. Jr., eds.).  Elsevier, New York  pp. 254-259 (1988).
95. LAWSON, D., BRUCHOVSKY, N., RENNIE, P.S., GOLDENBERG, L. and FLETCHER, T.:
Relative effectiveness of androgen withdrawal therapies as measured by changes in the intracellular distributions of androgen receptors and dihydrotestosterone. In "Hormones and Cancer 3", Progress in Cancer Research and Therapy, Vol. 35, (Bresciani, F., Lippman, M.E., King, R.J.B. and Raynaud J.P., eds.).  Raven Press, New York  pp. 488-495 (1988).
96. BRUCHOVSKY, N., RENNIE, P.S., GOLDENBERG, S.L., and COPPIN, C.M.L.:
Limitations of androgen withdrawal therapy of prostatic carcinoma - the next step? Proc. Second Tokyo Symposium Prostatic Carcinoma.  Elsevier, New York  pp. 1-10 (1989).
97. PETROW, V., PADILLA, G.M., McPHAIL, A.T., BRUCHOVSKY, N. and SCHNEIDER, S.L.:
Prostate III. - A structural feature characteristic of the rat prostate 5α-reductase active site.  J Steroid Biochem  32:399-407 (1989).
98. HO, K.C., SNOEK,R., QUARMBY, V., VISKOCHIL, D.H., RENNIE, P.S., WILSON, E.M., FRENCH, F.S. and BRUCHOVSKY, N.:
Primary structure and androgen regulation of a 20-kdal protein specific to rat ventral prostate.  Biochemistry  28:6367-6373 (1989).
99. RENNIE, P.S., BOWDEN, J.F., FREEMAN, S.N., BRUCHOVSKY, N., CHENG, H., WILSON, E.M., FRENCH, F.S. and MAIN, L.:
Cortisol alters gene expression during involution of the rat ventral prostate.  Mol Endocrinol  3:703-708 (1989).
100. BRUCHOVSKY, N.:
New approaches to the understanding of hormonal therapy of prostatic cancer. In "Urologic Oncology Today & Tomorrow", Symposium Proceedings, (Trachtenberg, J., ed.).  Stratagem Communications, Don Mills  pp. 95-101 (1989).
101. BRUCHOVSKY, N., RENNIE, P.S., COLDMAN, A.J., GOLDENBERG, S.L., TO, M. and LAWSON, D.:
Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma.  Cancer Res  50:2275-2282 (1990).
102. JONES, E.C., McNEAL, J., BRUCHOVSKY, N. and de JONG, G.:
DNA content in prostatic adenocarcinoma. A flow cytometry study of the predictive value of aneuploidy for tumor volume, percentage Gleason grade 4 and 5, and lymph node metastases.  Cancer  66:752-757 (1990).
103. RENNIE, P.S., BRUCHOVSKY, N. and COLDMAN, A.J.:
Loss of androgen dependence is associated with an increase in tumorigenic stem cells and resistance to cell-death genes.  J Steroid Biochem Mol Biol  37:843-847 (1990).
104. BRUCHOVSKY, N.:
Preface "Out of sight, out of mind". In "The Prostate as an Endocrine Gland", (Farnsworth, W.F. and Ablin, R.J., eds.).  CRC Press, Inc., Boca Raton  (1990).
105. GOLDENBERG, S.L. and BRUCHOVSKY, N.:
Use of cyproterone acetate in prostate cancer.  Urol Clin N Amer  18:111-121 (1991).
106. BRUCHOVSKY, N:
Androgens and Anti-androgens. In "Cancer Medicine" 3rd Edition (Holland, J.F., Frei III, E., Bast, R.C., Kufe, D.W., Morton, D.L. and Weichselbaum, R.R., eds.).  Lea & Febiger, Philadelphia  pp. 884-896 (1993).
107. RENNIE, P.S., BRUCHOVSKY, N., LECO, K.J., SHEPPARD, P.C., McQUEEN, S.A., CHENG, H., SNOEK, R., HAMEL, A., BOCK, M.E., MACDONALD, B.S., NICKEL, B.E., CHANG, C., LIAO, S., CATTINI, P.A. and MATUSIK, R.J.:
Characterization of two cis-acting DNA elements involved in the androgen regulation of the probasin gene.  Mol Endocrinol  7:23-36 (1993).
108. AKAKURA, K., BRUCHOVSKY, N., GOLDENBERG, S.L., RENNIE, P.S., BUCKLEY, A.R. and SULLIVAN, L.D.:
Effects of intermittent androgen suppression on androgen-dependent tumors: Apoptosis and serum prostate-specific antigen.  Cancer  71:2782-2790 (1993).
109. BRUCHOVSKY, N., GOLDENBERG, S.L., AKAKURA, K. and RENNIE, P.S.:
LHRH agonists in prostate cancer: Elimination of flare reaction by pretreatment with cyproterone acetate and low-dose diethylstilbestrol.  Cancer  72(5):1686-1691 (1993).
110. RENNIE, P.S., MAWJI, N.R., COLDMAN, A.J., GODOLPHIN, W., JONES, E.C., VIELKIND, J.R., and BRUCHOVSKY, N.:
Relationship between variant forms of estrogen receptor RNA and an apoptosis-related RNA, TRPM-2, with survival in breast cancer patients.  Cancer  72:3648-3654 (1993).
111. BRUCHOVSKY, N., GOLDENBERG, S.L. and GLEAVE, M.:
Intermittent hormonal therapy for prostate cancer. In "Urologic Oncology Update", Symposium Proceedings, (Elhilali, M., ed.).  Stratagem Communications, Don Mills  pp. 33-37 (1993).
112. RENNIE, P.S., BRUCHOVSKY, N., AKAKURA, K., GOLDENBERG, S.L., OTAL, N., AKAKURA, S., WONG, P. and TENNISWOOD, M.:
Effect of tumor progression on the androgenic regulation of the androgen receptor, TRPM-2 and YPTI genes in the Shionogi carcinoma.  J Steroid Biochem Mol Biol  50:31-40 (1994).
113. DEDHAR, S., RENNIE, P.S., SHAGO, M., LEUNG-HAGESTEIGN, C.Y., YANG, H., FILMUS, J., HAWLEY, R.G., BRUCHOVSKY, N., CHENG, H., MATUSIK, R.J. and GIGUERE, V.:
Inhibition of nuclear hormone receptor activity by calreticulin.  Nature  367:480-483 (1994).
114. BRUCHOVSKY, N., AKAKURA, K., RENNIE, P.S. and GOLDENBERG, S.L.:
Adverse effects of androgen ablation on stem cells and clusterin synthesis in the Shionogi carcinoma. In "Fundamental Approaches to the Diagnosis and Treatment for Prostate Cancer and BPH", (Imai, K., Shimazaki, J., and Karr, J.P.).  Adenine Press, Schenectady  pp. 103-104 (1994).
115. BRUCHOVSKY, N., AKAKURA, K., GOLDENBERG, S.L., GLEAVE, M., RENNIE, P.S. and SULLIVAN, L.:
Intermittent androgen suppression in the treatment of prostate cancer. In "Fundamental Approaches to the Diagnosis and Treatment of Prostate Cancer and BPH", (Imai, K., Shimazaki, J. and Karr, J.P.).  Adenine Press, Schenectady  pp. 187-197 (1994).
116. KASPER, S., RENNIE, P.S., BRUCHOVSKY, N., SHEPPARD, P.C., CHENG, H., LIN, L., SNOEK, R. and MATUSIK, R.J.:
Cooperative binding of androgen receptors to two DNA sequences is required for androgen induction of the probasin gene.  J Biol Chem  50:31763-31769 (1994).
117. GOUT, P.W., HORSMAN, D.E., FOX, K., de JONG, G., MA, S. and BRUCHOVSKY, N.:
The rat Nb2 lymphoma: a novel model for tumor progression.  Anticancer Res  14:2485-2492 (1994).
118. BRUCHOVSKY, N.:
The rationale for intermittent androgen-suppression therapy in prostate cancer.  Prospectives  4(6):6-8 (1994).
119. RENNIE, P.S., BRUCHOVSKY, N., AKAKURA, K., GOLDENBERG, S.L., GLEAVE, M.E. and SULLIVAN, L.D.:
Apoptosis in relation to androgen independence in experimental and clinical prostate cancer. In "Apoptosis in Hormone Dependent Cancers", (Michna, H. and Tenniswood, M., eds.).  Springer-Verlag, Berlin  pp. 71-82 (1995).
120. GOLDENBERG, S.L., BRUCHOVSKY, N., GLEAVE, M.E., SULLIVAN, L.D. and AKAKURA, K.:
Intermittent androgen suppression in the treatment of prostate cancer. A preliminary report.  Urology  45:839-845 (1995).
121. BRUCHOVSKY, N., GOLDENBERG, S.L., RENNIE, P.S. and GLEAVE, M.E.:
Theoretische Überlegungen und erste klinische Ergebnisse mit intermittierender Hormon-behandlung bei Patienten mit einem fortgeschrittenen Prostatakarzinom.  Urologe  [A] 34:389-392 (1995).
122. BRUCHOVSKY, N., GOLDENBERG, S.L., GLEAVE, M.E., AKAKURA, K., SATO, N. and RENNIE, P.S.:
Intermittent androgen blockade. In "Proceedings of the International Conference on Prostatic Carcinoma", (Abrahamson, P.A. and Iversen, P., eds.).  Wells Medical Limited, Royal Tunbridge Wells  pp. 43-47 (1995).
123. Gleave, M.E., GOLDENBERG, S.L. and Bruchovsky, N.:
Prostate-specific antigen as a prognostic predictor for prostate cancer. In "Hormone-Dependent Cancer", (Pasqualini, J.R. and Katzenellenbogen, B.S., eds.).  Marcel Dekker Inc., New York  pp.425-452 (1996).
124. SATO, N., GLEAVE, M.E., BRUCHOVSKY, N., RENNIE, P.S., GOLDENBERG, S.L., LANGE, P., and SULLIVAN, L.D.:
Intermittent androgen suppression delays progression to androgen-independent regulation of prostate specific antigen gene in the LNCaP prostate tumour model.  J Steroid Biochem Mol Biol  58(2):139-146 (1996).
125. SNOEK, R., RENNIE, P.S., MATUSIK, R.J., SHEPPARD, P.C. and BRUCHOVSKY, N.:
Induction of cell-free, in vitro transcription by recombinant androgen receptor peptides.  J Steroid Biochem Mol Biol  59(3/4):243-250 (1996).
126. AKAKURA, K., BRUCHOVSKY, N., RENNIE, P.S., COLDMAN, A.J., GOLDENBERG, S.L., TENNISWOOD, M. and FOX, K.:
Effects of intermittent androgen suppression on the stem cell composition and the expression of the TRPM-2 (clusterin) gene in the Shionogi carcinoma.  J Steroid Biochem Mol Biol  59(5/6):501-511 (1996).
127. KAEFER, M., AUDIA, J.E., BRUCHOVSKY, N., GOODE, R.L., HSIAO, K.C., KRUSHINSKI, J.H., LEIBOVITZ, I.Y., LEE, C., STEIDLE, C.P., SUTKOWSKI, D.M. and NEUBAUER, B.L.:
Characterization of type 1 5α-reductase activity in DU-145 human prostate adenocarcinoma cells.  J Steroid Biochem Mol Biol  58(2):195-205 (1996).
128. BRUCHOVSKY, N., SNOEK, R., RENNIE, P.S., AKAKURA, K., GOLDENBERG, S.L. and GLEAVE, M.E.:
Control of tumor progression by maintenance of apoptosis.  The Prostate  6:Suppl:13-21 (1996).
129. GOLDENBERG, S.L., BRUCHOVSKY, N., GLEAVE, M.E. and SULLIVAN, L.D.:
Low-dose cyproterone acetate plus mini-dose diethylstilbestrol - a protocol for reversible medical castration.  Urology  47:882-884 (1996).
130. GLEAVE, M.E., GOLDENBERG, S.L., JONES, E.C., BRUCHOVSKY, N., KINAHAN, J. and SULLIVAN, L.D.:
Optimal duration of neoadjuvant withdrawal therapy prior to radical prostatectomy in clinically confined prostate cancer.  Seminars Urol Oncol  14:Suppl 2:39-47 (1996).
131. GLEAVE, M.E., GOLDENBERG, S.L., JONES, E.C., BRUCHOVSKY, N. and SULLIVAN, L.D.:
Biochemical and pathological effects of eight months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer.  J Urol  155:213-219 (1996).
132. GLEAVE, M.E., SATO, N., RENNIE, P.S., GOLDENBERG, S.L., BRUCHOVSKY, N. and SULLIVAN, L.D.:
Echappement hormonal et hormonothérapie intermittente dans le modèle LNCaP de cancer prostatique humain.  Progrès en Urology  6:6:375-385 (1996).
133. BRUCHOVSKY, N., SADAR, M.D., AKAKURA, K., GOLDENBERG, S.L., MATSUOKA, K. and RENNIE, P.S.:
Characterization of 5α-reductase gene expression in stroma and epithelium of human prostate.  J Steroid Biochem Mol Biol  59:397-404 (1996).
134. GOLDENBERG, S.L., BRUCHOVSKY, N. and GLEAVE, M.E.:
The role of intermittent androgen blockade in prostate cancer.  Horm Ther Androl Urol  1:21-25 (1996).
135. GLEAVE, M.E., BRUCHOVSKY, N., GOLDENBERG, S.L., SATO, N. and RENNIE, P.S.:
Intermittent androgen suppression.  Urol Int  3:8-10 (1996).
136. HALL, R., HEDLUND, P.O., ACKERMANN, R., BRUCHOVSKY, N., DALESIO, O., DEBRUYNE, F., MURPHY, G.P., PARMAR, M.K.B., PAVONE-MACALUSO, M., RUUTU, M. and SMITH, P.:
Evaluation and follow up of patients with N1-3 MO or NXM1 prostate cancer in phase III trials.  Urology  49:Suppl:39-45 (1997).
137. GOUT, P.W., KANG, Y.J., BUCKLEY, D.J., BRUCHOVSKY, N. and BUCKLEY, A.R.:
Increased cystine uptake capability associated with malignant progression of Nb2 lymphoma cells.  Leukemia  11:1329-1337 (1997).
138. SATO, N., GLEAVE, M.E., BRUCHOVSKY, N., RENNIE, P.S., BERALDI, E. and SULLIVAN, L.D.:
A metastatic and androgen-sensitive human prostate cancer model using intraprostatic inoculation of LNCaP cells in SCID mice.  Cancer Res  57:1584-1589 (1997).
139. BRUCHOVSKY, N., GOLDENBERG, S.L. and GLEAVE, M.E.:
Intermittent hormonal therapy for prostate cancer.  Adv Urol  10:291-326 (1997).
140. SATO, N., SADAR, M.D., BRUCHOVSKY, N., SAATCIOGLU, F., RENNIE, P.S., SATO, S., LANGE, P.H. and GLEAVE, M.E.:
Androgenic induction of prostate-specific antigen gene is repressed by protein-protein interaction between the androgen receptor and AP-1/c-Jun in the human prostate cancer cell line LNCaP.  J Biol Chem  272:17485-17494 (1997).
141. BRUCHOVSKY, N., GOLDENBERG, S.L., GLEAVE, M.E., RENNIE, P.S., AKAKURA, K. and SATO, N.:
Intermittent therapy for prostate cancer.  Endocrine-Related Cancer  4:153-177 (1997).
142. BRUCHOVSKY, N.:
Androgens and Anti-androgens. In "Cancer Medicine" 4th Edition (Holland, J.F., Frei III, E., Bast, R.C., Kufe, D.W., Morton, D.L. and Weichselbaum, R.R., eds.).  Williams & Wilkins, Baltimore, Maryland  pp. 1133-1148 (1997).
143. GLEAVE, M.E., GOLDENBERG, S.L., JONES, E.C., BRUCHOVSKY, N. and SULLIVAN, L.D.:
Longer duration of neoadjuvant hormonal therapy prior to radical prostatectomy in clinically confined prostate cancer: biochemical and pathological effects.  Mol Urol  1:199-205 (1997).
144. GLEAVE, M.E., SATO, N., GOLDENBERG, S.L., STOTHERS, M.L., BRUCHOVSKY, N. and SULLIVAN, L.D.,:
Neoadjuvant androgen withdrawal therapy decreases local recurrence rates following tumor excision in the Shionogi tumor model.  J Urol  157:1727-1730 (1997).
145. GOLDENBERG, S.L., GLEAVE, M.E. and BRUCHOVSKY, N.:
Mechanisms of androgen-independent tumor growth.  Can J Urol  4(2):Suppl:65-67 (1997).
146. GOLDENBERG, S.L., GLEAVE, M.E., BRUCHOVSKY, N. and RENNIE, P.S.:
Letters to the Editor, RE: Editorial Comment (P.C. Walsh. J Urol 156:1523-1524, 1996).  J Urol  157:2267 (1997).
147. GLEAVE, M.E., BRUCHOVSKY, N., GOLDENBERG, S.L. and RENNIE, P.S.:
Intermittent androgen suppression: rationale and clinical experience. In "Recent Advances in Prostate Cancer", (Schroeder, F., ed).  The Parthenon Publishing Group Ltd., New York USA, and Carnforrth, UK  pp. 109-120 (1997).
148. GOLDENBERG, S.L. and BRUCHOVSKY, N.:
Androgen withdrawal therapy: new perspectives in the treatment of prostate cancer. In "Principles and Practice of Genitourinary Oncology", (Raghavan, D., Scher, H.I., Leibel, S.A. and Lange, P., eds.).  J.B. Lippincott Company, Philadelphia  57:583-591 (1997).
149. GLEAVE, M.E., SATO, N., SADAR, M.D., YAGO, V., BRUCHOVSKY, N. and SULLIVAN, L.D.:
Butyrate analogue, isobutyramide, inhibits tumor growth and time to androgen-independent progression in the human prostate LNCaP tumor model.  J Cell Biochem  69:271-281 (1998).
150. SNOEK, R., BRUCHOVSKY, N., KASPER, N., MATUSIK, R.J., GLEAVE, M.E., SATO, N., MAWJI, N.R. and RENNIE, P.S.:
Differential transactivation by the androgen receptor in prostate cancer cells.  The Prostate  36:256-263 (1998).
151. BRUCHOVSKY, N., GOLDENBERG, S.L. and GLEAVE, M.E.:
Intermittent androgen suppression for the treatment of prostate cancer: In "New Perspectives in Prostate Cancer", (Belldegrun, A., Kirby, R.S. and Oliver, T., eds.).  Isis Medical Medial Ltd., Oxford  pp. 273-282 (1998).
152. GLEAVE, M.E., GOLDENBERG, S.L., JONES, E.C., BRUCHOVSKY, N. and SULLIVAN, L.D.:
Long-term neoadjuvant hormone therapy prior to radical prostatectomy: analysis of outcome by pre-operative risk factors.  Mol Urol  2:171-177 (1998).
153. GLEAVE, M.E., GOLDENBERG, S.L., BRUCHOVSKY, N. and RENNIE, P.S.:
Intermittent androgen suppression for prostate cancer: rationale and clinical experience.  Prostate Cancer and Prostatic Diseases  1:289-296 (1998).
154. GOLDENBERG, S.L., GLEAVE, M.E. and BRUCHOVSKY, N.:
The role of intermittent androgen suppression in prostate cancer.  Amer Urol Assoc Update Ser  17:18-23 (1999).
155. BRUCHOVSKY, N., KLOTZ, L.H., CROOK, J.M., ARMITAGE, G.R., HOFFART, D., GLEAVE, M.E. and GOLDENBERG, S.L.:
Intermittent endocrine therapy for prostate cancer. In "Renal, Bladder and Prostate Cancer: an Update" (Schroeder, F.H., ed).  Parthenon Publishing, Carnforth  pp. 203-209 (1999).
156. GLEAVE, M.E., BRUCHOVSKY, N., MOORE, M.J. and VENNER, P.:
Prostate Cancer: 9. Treatment of advanced disease.  Can Med Assoc J  2:225-32 (1999).
157. GOLDENBERG, S.L., GLEAVE, M.E., TAYLOR, D. and BRUCHOVSKY, N.:
Clinical experience with intermittent androgen suppression in prostate cancer: Minimum of 3 years' follow-up.  Mol Urol  3(3):287-293 (1999).
158. KASPER, S., RENNIE, P.S., BRUCHOVSKY, N., LIN, L., CHENG, H., SNOEK, R., DAHLMAN-WRIGHT, K., GUSTAFSSON, J-A., SHIU R.P.C., SHEPPARD, P.C. and MATUSIK R.J.
Selective activation of the probasin androgen-responsive region by steroid hormones.  J Mol Endocrinol  22:313-325 (1999).
159. SADAR, M.D., HUSSAIN, M. and BRUCHOVSKY, N.:
Prostate cancer: molecular biology of early progression to androgen independence.  Endocrine-Related Cancer  6:487-502 (1999).
160. BRUCHOVSKY, N.:
Synopsis: Dyhdrotestosterone - the active form of testosterone.    (1999).
161. BRUCHOVSKY, N. and WILSON, J.D.:
Personal history: Discovery of the role of dihydrotestosterone in androgen action.  Steroids  64:753-759 (1999).
162. NELSON, C.C., HENDY, S.C., SHUKIN, R.J., CHENG, H., BRUCHOVSKY, N., KOOP, B.F. and RENNIE, S.R.:
Determinants of DNA sequence specificity of the androgen, progesterone, and glucocorticoid receptors: Evidence of differential steroid receptor response elements.  Mol Endocrinol  13:2090-2107 (1999).
163. BRUCHOVSKY, N., KLOTZ, L.H., SADAR, M., CROOK, J.M., HOFFART, D., GODWIN, L., WARKENTIN, M., GLEAVE, M.E.and GOLDENBERG, S.L.:
Intermittent androgen suppression for prostate cancer: Canadian prospective trial and related observations.  Mol Urol  4(3):191-199 (2000).
164. GLEAVE, M.E., La BIANCA, S.E., GOLDENBERG, S.L., JONES, E.C., BRUCHOVSKY, N. and SULLIVAN, L.D.:
Long-term neoadjuvant hormone therapy prior to radical prostatectomy: Evaluation of risk for biochemical recurrence at 5-year follow-up.  Urol  56(2):289-294 (2000).
165. BRUCHOVSKY, N., THEYER, G.:
2nd International Workshop on Intermittent Androgen Ablation Therapy, Meeting Report.  Euro Urol Today  11(3):4-5 (2000).
166. TILLEY, W.D., CLARKE, C.L., BIRRELL, S.N. and BRUCHOVSKY, N.:
Hormones and cancer: new insights, new challenges.  Trends Endocrinol Metab  12(5):186-188 (2001).
167. BRUCHOVSKY, N., GOLDENBERG, S.L., MAWJI, N.R. and SADAR, M.D.:
Evolving aspects of intermittent androgen blockade for prostate cancer: diagnosis and treatment of early tumor progression and maintenance of remission.  Proc 7th Int Congr Androl  pp. 609-623, (2001).
168. GOUT, P.W., BUCKLEY, A.R., SIMMS, C.R., and BRUCHOVSKY, N.:
Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the xc -cystine transporter: A new action for an old drug.  Leukemia  15(10):1633-1640 (2001).
169. UEDA, T., BRUCHOVSKY, N. and SADAR, M.D.:
Activation of the androgen receptor N-terminal domain by IL-6 via MAPK and STAT3 signal transduction pathways.  J Biol Chem  277(9):7076-7085 (2002).
170. UEDA, T., MAWJI, N.R., BRUCHOVSKY, N. and SADAR, M.D.:
Ligand-independent activation of the androgen receptor by IL-6 and the role of steroid receptor coactivator -1 in prostate cancer cells.  J Biol Chem  277(41):38087-38094 (2002).
171. BLASZCZYK, N., MASRI, B.A., MAWJI, N.R., UEDA, T., McALINDEN, G., DUNCAN, C.P., BRUCHOVSKY, N., SCHWEIKERT, H., SCHNABEL, D. JONES, E.C. and SADAR, M.D.:
Osteoblast-derived factors induce androgen-independent proliferation and expression of prostate-specific antigen in human prostate cancer cells.  Clin Cancer Res  10:1860-1869 (2004).
172. ANDRIOLE, G., BRUCHOVSKY, N., CHUNG, L., MATSUMOTO, A., RITTMASTER, R., ROEHRBORN, C., RUSSELL, D. and TINDALL, D.:
Dihydrotestosterone (DHT) and the prostate: The scientific rationale for 5α-reductase inhibitors in the treatment of benign prostatic hyperplasia.  J Urol  172:1399-1403 (2004).
173. BRUCHOVSKY, N., KLOTZ, L., CROOK, J., MALONE, S., LUDGATE, C., MORRIS, W.J., GLEAVE, M.E., and GOLDENBERG, S.L.:
Final results of the Canadian prospective phase II trial of intermittent androgen suppression for men in biochemical relapse after radiotherapy for locally advanced prostate cancer - clinical parameters.  Cancer  107:389-395 (2006).
174. BRUCHOVSKY, N., KLOTZ, L., CROOK, J., and GOLDENBERG, S.L.:
Locally advanced prostate cancer - Biochemical results from a prospective phase II trial of intermittent androgen suppression in men with evidence of PSA relapse after radiotherapy. Cancer 109:858-867 (2006).
175.

BRUCHOVSKY, N., KLOTZ, L., and CROOK, J. Reply to Locally Advanced Prostate Cancer – Biochemical Results From a Prospective Phase II Study of Intermittent Androgen Suppression for Men With Evidence of Prostate-Specific Antigen Recurrence After Radiotherapy. Cancer 110:468 (2007).

176.

BRUCHOVSKY, N., KLOTZ, L., CROOK, J., PHILLIPS. N., ABERSBACH.J., and GOLDENBERG, LS. Quality of Life, Morbidity and Mortality Results fr om a Prospective Phase II Study of Intermittent Androgen Sup pre ssion for Men with Evidence of PSA Relapse after Radiotherapy for Locally Advanced Prostate Cancer. Clin Genitourinary Cancer 6:46-52 (2008).

177.

BRUCHOVSKY, N., KLOTZ, L., CROOK, J., PHILLIPS. N., ABERSBACH.J., and GOLDENBERG, LS. Quality of Life, Morbidity and Mortality Results fr om a Prospective Phase II Study of Intermittent Androgen Sup pre ssion for Men with Evidence of PSA Relapse after Radiotherapy for Locally Advanced Prostate Cancer. Clin Cancer Update: 2008 In Review 82-88 (2008).

178.

HIRATA, Y., BRUCHOVSKY, N., and AIHARA, K. Development of a Mathematical Model that Predicts the Outc om e of Hormone Therapy for Prostate Cancer. J Theor Biol 264:517-527 (2010).

179.

SUZUKI, T., BRUCHOVSKY, N., and AIHARA, K. Piecewise Affine Systems Modelling for Optimizing Hormone Therapy of Prostate Cancer. Philos Transact A Math Phys Eng Sci 368(1930):5045-5059 (2010).

180.

TANAKA, G., HIRATA, Y., GOLDENBERG, S.L., BRUCHOVSKY, N., and AIHARA, K. Mathematical Modelling of Prostate Cancer Growth and its Application to Hormone Therapy. Philos Transact A Math Phys Eng Sci 368:5029-5044 (2010).

181.

LOCKE, J. and BRUCHOVSKY, N. Prostate Cancer: Finasteride Extends PSA Doubling Time During Intermittent Hormone Therapy. Can J Urol 17(3):5162-5169 (2010).

182.

HIRATA, Y., di BERNARDO, M., BRUCHOVSKY, and N., AIHARA, K. Hybrid Optimal Scheduling for Intermittent Androgen Sup pre ssion of Prostate Cancer. Chaos 20(4):pp. 045125 1-10 (2010).

183.

KURAMAE, H., HIRATA, Y., BRUCHOVSKY, N., AIHARA, K. and SUZUKI, H. Nonlinear Systems Identification by Combining Regression with Bootstrap Resampling. Chaos. 21(4): 043121 1-12 (2011).

184.

HIRATA, Y., TANAKA, G., BRUCHOVSKY, N., and AIHARA, K. Mathematically Modelling and Controlling Prostate Cancer Under Intermittent Hormone Therapy. Asian J Andrology. 14:270-277 (2012).

185.

HIRATA, Y., AKAKURA, K., HIGANO, C.S., BRUCHOVSKY, N. and AIHARA, K. Quantitative mathematical modeling of PSA dynamics of prostate cancer patients treated with intermittent androgen suppression. J Mol Cell Biol. (accepted).

Abstracts

1. BRUCHOVSKY, N. and WILSON, J.D.:
Evidence that dihydrotestosterone is the active form of testosterone.  Clin Res  16:74 (1968).
2. BRUCHOVSKY, N. and WILSON, J.D.:
The mechanism of action of testosterone in rat prostate.  J Clin Invest  47:12a (1968).
3. BRUCHOVSKY, N.:
Factors that regulate the action of testosterone, dihydrotestosterone and androstandiol in rat prostate.  Clin Res  18:718 (1970).
4. BROWN, J. and BRUCHOVSKY, N.:
A mechanism of androgen control demonstrated in human skin.  Clin Res  19:770 (1971).
5. BRUCHOVSKY, N.:
Cell division induced by 5a-dihydrotestosterone.  Clin Res  19:770 (1971).
6. BRUCHOVSKY, N.:
Dihydrotestosterone - A common factor in the action of androgens.  Clin Res  19:368 (1971).
7. RENNIE, P.S. and BRUCHOVSKY, N.:
Comparison of the intracellular binding of testosterone and dihydrotestosterone.  Proc Can Fed Soc  14:237 (1971).
8. RENNIE, P.S. and BRUCHOVSKY, N.:
Effect of binding protein on androgen localization in target tissues.  IV Int Congr Endocrinol Abstr Short Commun  p. 79 (1972).
9. RENNIE, P.S. and BRUCHOVSKY, N.:
Turnover of protein bound androgens.  Proc Can Fed Biol Soc  15:412 (1972).
10. LESSER, B. and BRUCHOVSKY, N.:
Regulation of prostatic growth by androgens.  Proc Can Fed Biol Soc  15:413 (1972).
11. RENNIE, P.S. and BRUCHOVSKY, N.:
Androgen uptake by prostatic nuclei.  Clin Res  20:923 (1972).
12. BRUCHOVSKY, N. and MEAKIN, J.W.:
Androgen uptake and binding by mammary tumours.  Clin Res  20:947 (1972).
13. LESSER, B. and BRUCHOVSKY, N.:
Androgenic regulation of prostatic growth and function.  Clin Res  20:921 (1972).
14. RENNIE, P.S. and BRUCHOVSKY, N.:
Androgen binding proteins of the rat prostate.  Proc Can Fed Biol Soc  16:8 (1973).
15. LESSER, B. and BRUCHOVSKY, N.:
Cell proliferation kinetics in androgen-stimulated rat prostate.  Proc Can Fed Biol Soc  16:196 (1973).
16. BRUCHOVSKY, N. and RENNIE, P.S.:
Transport of androgens in prostatic cells.  Clin Res  21:1023 (1973).
17. BRUCHOVSKY, N. and SUTHERLAND, D.J.:
The incorporation of androgens into nuclei of dependent and autonomous mammary tumour cells.  Clin Res  21:1066 (1973).
18. LESSER, B., CRAVEN, S. and BRUCHOVSKY, N.:
Androgen-stimulated growth of rat prostate is independent of cyclic AMP.  Proc Can Fed Biol Soc  17:625 (1974).
19. CRAVEN, S. and BRUCHOVSKY, N.:
Transfer of androgens into nuclei of prostatic cells in the absence of cytoplasmic receptors.  Clin Res  22:730 (1974).
20. VAN DOORN, E.J. and BRUCHOVSKY, N.:
Synthesis of nuclear androgen receptor.  Clin Res  23:619A (1975).
21. BRUCHOVSKY, N.:
Asymmetry of androgen metabolism in benign prostatic hyperplasia.  Annu Roy Coll Phys Surg Can  9:29 (1976).
22. WATSON, G.K., MORGAN, A.R. and BRUCHOVSKY, N.:
Androgen regulation of superhelical DNA untwisting enzyme.  V Int Congr Endocrinol Abstr Short Commun  p. 14 (1976).
23. KOAT, A., CRAVEN, S. and BRUCHOVSKY, N.:
A mechanism of control of cytoplasmic androgen receptor concentration.  V Int Congr Endocrinol Abstr Short Commun  p. 15 (1976).
24. VAN DOORN, E.J. and BRUCHOVSKY, N.:
Synthesis of nuclear androgen receptor in prostatic cells in vivo.  V Int Congr Endocrinol Abstr Short Commun  p. 148 (1976).
25. BRUCHOVSKY, N.:
Asymmetry of androgen metabolism in benign prostatic hyperplasia.  V Int Congr Endocrinol Abstr Short Commun  p. 186 (1976).
26. RENNIE, P.S., VAN DOORN, E. and BRUCHOVSKY, N.:
Analysis of cytoplasmic and nuclear forms of androgen receptors.  Clin Res  24:662A (1976).
27. LIESKOVSKY, G.J. and BRUCHOVSKY, N.:
Quantitation of androgen receptors in human prostate.  Annu Roy Coll Phys Surg Can  10:46 (1976).
28. RENNIE, P.S., KOAT, A. and BRUCHOVSKY, N.:
Androgenic regulation of acid phosphatase activity of rat ventral prostate.  Endocrine Soc (U.S.A.) Program Abstr 59th Annu Mtg  p. 85 (1977).
29. VAN DOORN, E.J. and BRUCHOVSKY, N.:
Mechanisms of replenishment of nuclear androgen receptor in the rat ventral prostate.  Clin Res  25:685A (1977).
30. RENNIE, P.S., BRUCHOVSKY, N. and NOBLE, R.L.:
Acid phosphatase activity and nuclear binding of androgens in prostatic tumours of Noble rats.  Clin Res  25:710A (1977).
31. VAN DOORN, E.J. and BRUCHOVSKY, N.:
Nuclear binding of 3H-estradiol in human breast cancer.  Ann Roy Coll Phys Surgs Can  11:89 (1978).
32. CALLAWAY, T., BRUCHOVSKY, N. and RENNIE, P.S.:
Effects of anti-androgenic compounds on translocation of prostatic androgen receptor.  Endocrine Soc (U.S.A.) Program Abstr 60th Annu Mtg  p. 298 (1978).
33. CALLAWAY, T.W., BRUCHOVSKY, N., RENNIE, P.S. and COMEAU, T.:
Regulation of nuclear abundance of dihydrotestosterone (DHT): evidence for non-receptor mediated processes.  XI Int Congr Biochem Abstr Short Commun  p. 614 (1979).
34. RENNIE, P.S., BRUCHOVSKY, N. and MO, S.:
Elevated levels of plasminogen activator in prostatic tumors of Nb rats.  Cancer Treat Rep  63:1211 (1979).
35. DE LARMINAT, M.A., BRUCHOVSKY, N., RENNIE, P.S. and TERTZAKIAN, G.:
Use of affinity chromatography for the purification of nuclear androgen-receptors.  Clin Res  28:670A (1980).
36. RENNIE, P.S., BRUCHOVSKY, N. and DE JONG, G.:
Plasminogen activator is activated in carcinoma of the human prostate and associated with decreased androgen-receptor levels.  Endocrine Soc Program Abstr 63rd Annu Mtg  p. 369 (1981).
37. RENNIE, P.S., BRUCHOVSKY, N. and FILIPENKO, J.D.:
Androgenic regulation of superhelical DNA nicking - closing enzyme in rat ventral prostate.  Clin Invest Med  15B (1981).
38. EMERMAN, J.T., LEAHY, M., GOUT, P.W. and BRUCHOVSKY, N.:
A possible role for growth hormone in human breast cancer.  Clin Invest Med  24B (1981).
39. LEAHY, M., EMERMAN, J.T., BRUCHOVSKY, N., TZE, W.J., NOBLE, R.L., BEER, C.T. and GOUT, P.W.:
Mitogenic activity of lactogenic hormones in sera from adults and children.  Clin Invest Med  15B (1981).
40. RENNIE, P.S., De LARMINAT, M.A. and BRUCHOVSKY, N.:
The relationship of nuclear concentrations of dihydrotestosterone to androgen-receptors and androgen-mediated responses.  Endocrine Soc Programr Abstr 64th Annu Mtg  p. 351 (1982).
41. GILES, M.G., BRUCHOVSKY, N. and RENNIE, P.S.:
Androgen regulated gene expression in Shionogi carcinoma.  Endocrine Soc Program Abstr 65th Annu Mtg  p. 122 (1983).
42. RENNIE, P.S., BRUCHOVSKY, N. and CHENG, H.:
Extraction of 3s androgen-receptors from salt resistant fractions and nuclear matrices of prostatic nuclei.  Endocrine Soc Program Abstr 65th Annu Mtg  p. 136 (1983).
43. RENNIE, P.S., BRUCHOVSKY, N., CHENG, H. AND FOEKENS, J.A.:
Turnover of 3s androgen receptors bound to the nuclear matrix of prostatic nuclei.  J Steroid Biochem  19:Suppl:130S (1983).
44. GOUT, P.W., PRIOR, J.C., RENNIE, P.S. and BRUCHOVSKY, N.:
Multiple forms of serum prolactin in hyperprolactinemia as shown by bioassay: effects of treatment of bromocryptine.  J Steroid Biochem  19:Suppl:139S (1983).
45. DUNSTAN-ADAMS, E., BRUCHOVSKY, N., RENNIE, P.S., GOLDENBERG, S.L. and McLOUGHLIN, M.:
Kinetic parameters of 5a-reductase activity and inhibition in stroma and epithelium of human prostate.  The Prostate  5:332 (1984).
46. GOLDENBERG, S.L., GILES, M.G., BRUCHOVSKY, N. and RENNIE, P.S.:
Protein electrophoretic profiles of prostatic stroma and epithelium.  The Prostate  5:336 (1984).
47. CRANE, S., FOEKENS, J., GOLDENBERG, S.L., BRUCHOVSKY, N. and RENNIE, P.S.:
The intracellular distributions of androgen receptor and dihydrotestosterone: A comparison between orchiectomy and anti-androgens.  The Prostate  5:338 (1984).
48. GOLDENBERG, S.L., COPPIN, C.M.L., BRUCHOVSKY, N., BROWN, E. and McLOUGHLIN, M.:
Cyproterone acetate plus mini-dose diethylstilbestrol: initial hormone therapy for advanced prostatic cancer.  The Prostate  5:342 (1984).
49. OTAL, N., BRUCHOVSKY, N., RENNIE, P.S. and GILES, M.G.:
Expression of androgen-related phenotypes during regression recurrent of the shionogi mammary carcinoma.  The Prostate  5:357 (1984).
50. TO, M., BRUCHOVSKY, N., RENNIE, P.S. and LEFEBVRE, Y.:
Isolation of chemically demonstrable quantities of nuclear androgen receptor.  The Prostate  5:359 (1984).
51. FOEKENS, J.A., RENNIE, P.S. and BRUCHOVSKY, N.:
Nuclear retention of dihydrotestosterone by non-receptor binding sites.  The Prostate  5:364 (1984).
52. GILES, M.G., BRUCHOVSKY, N. and RENNIE, P.S.:
The effects of androgens on the endogenous endonuclease in nuclei isolated from the Shionogi carcinoma.  The Prostate  5:367 (1984).
53. CHENG, H., RENNIE, P.S. and BRUCHOVSKY, N.:
The relationship of plasminogen activators to prostatic involution.  The Prostate  5:368 (1984).
54. FOEKENS, J.A., RENNIE, P.S., CHENG, H. and BRUCHOVSKY, N.:
Effects of micrococcal nuclease and trypsin on the release of androgen receptors covalently bound to the chromatin of rat prostates. 7th Int Congr  Endocrinol Abstr  p. 617 (1984).
55. TO, M., BRUCHOVSKY, N., RENNIE, P.S. and LEFEBVRE, Y.:
Isolation of chemically demonstrable quantities of nuclear androgen receptor.  7th Int Congr. Endocrinol Abstr  p. 1618 (1984).
56. BRUCHOVSKY, N., GOLDENBERG, S.L., COPPIN, E., BROWN, E. and McLOUGHLIN, M.:
Rationale for the use of cyproterone acetate and mini-dose diethylstilbestrol on the treatment of advanced prostatic cancer.  Proc Can Fed Biol Soc  28:39 (1985).
57. RENNIE, P.S., FOEKENS, J.A., CHENG, H. and BRUCHOVSKY, N.:
Androgen interactions with the nuclear matrix and chromatin of the rat prostate.  Proc Can Fed Biol Soc  28:37 (1985).
58. GOLDENBERG, S.L., BRUCHOVSKY, N., RENNIE, P.S. and McLOUGHLIN, M.G.:
Protein electrophoretic profiles of prostatic stroma.  J Urol  133:20 (1985).
59. GOLDENBERG, S.L., CRANE, S., FOEKENS, J., BRUCHOVSKY, N. and RENNIE, P.S.:
The intracellular distributions of androgen receptor and dihydrotestosterone: a comparison between orchiectomy and antiandrogens.  J Urol  133:39 (1985).
60. GOLDENBERG, S.L., COPPIN, C.M.L., BRUCHOVSKY, N. and McLOUGHLIN, M.G.:
Cyproterone acetate plus mini-dose diethylstilbestrol: initial hormone therapy for advanced prostatic cancer.  J Urol  133:157 (1985).
61. CHENG, H., RENNIE, P.S., FOEKENS, J.A. and BRUCHOVSKY, N.:
Covalent cross-linking and purification of androgen receptor-acceptor complexes.  Clin Invest Med  8:A74 (1985).
62. BRUCHOVSKY, N., GOLDENBERG, S.L., CRANE, S., FOEKENS, J.A. and RENNIE, P.S.:
Comparative effects of surgical and medical castration on the intracellular distributions of androgen receptors and dihydrotestosterone.  Clin Invest Med  8:A78 (1985).
63. OTAL, N., BRUCHOVSKY, N., RENNIE, P.S. and GILES, M.G.:
Expression of androgen related phenotypes during regression and recurrence of the Shionogi mammary carcinoma.  Clin Invest Med  8:A161 (1985).
64. GOUT, P.W., BRUCHOVSKY, N., RENNIE, P.S. and BEER, C.T.:
Prolactin markedly accelerates the recovery of butyrate - arrested cells of an autonomous Nb rat lymphoma subline.  Clin Invest Med  8:A161 (1985).
65. GOLDENBERG, S.L., COPPIN, C.M.L., BRUCHOVSKY, N., BROWN, E., RENNIE, P.S. and McLOUGHLIN, M.G.:
Cyproterone acetate plus mini - dose diethylstilbestrol: initial hormone therapy for advanced prostatic cancer.  Clin Invest Med  8:A164 (1985).
66. GOLDENBERG, S.L. and BRUCHOVSKY, N.:
Comparative effects of surgical and medical castration on the intracellular distributions of androgen receptor and dihydrotestosterone.  NW Urol Soc 32nd Annu Mtg Vancouver  (1985).
67. GOLDENBERG, S.L., COPPIN, C.M.L., BRUCHOVSKY, N., BROWN, E., RENNIE, P.S. and McLOUGHLIN, M.G.:
Cyproterone acetate plus mini - dose diethylstilbestrol: initial hormone therapy for advanced prostatic cancer.  NW Urol Soc 32nd Annu Mtg Vancouver  (1985).
68. GOUT, P.W., BRUCHOVSKY, N., RENNIE, P.S. and BEER, C.T.:
The resumption of growth of prolactin - independent Nb rat lymphoma cell cultures, which have been inhibited by sodium butyrate, is markedly stimulated by prolactin.  Endocrine Soc (U.S.A.) Program Abstr 67th Annu Mtg  p. 43 (1985).
69. DUNSTAN-ADAMS, E, BRUCHOVSKY, N., RENNIE, P.S., GOLDENBERG, S.L. and McLOUGHLIN, M.G.:
Regulation of dihydrotestosterone in human prostate by 5a-reductase and its inhibitors.  Clin Invest Med  8:A81 (1985).
70. GOLDENBERG, S.L., BRUCHOVSKY, N., RENNIE, P.S., COPPIN, C.M.L. and BROWN, E.:
Synergistic hormonal combinations in the treatment of advanced prostatic cancer.  Eur J Cancer Clin Oncol  22:718 (1986).
71. BOWDEN, J.F., RENNIE, P.S., CHENG, H. and BRUCHOVSKY, N.:
Protein components of nuclear androgen receptor acceptor sites in rat ventral prostate.  Endocrine Soc (U.S.A.) Program Abstr 68th Annu Mtg  p. 562 (1987).
72. SNOEK, R., BRUCHOVSKY, N. and RENNIE, P.S.:
Protein synthesis in stroma and epithelium of normal, castrated and stimulated rat ventral prostate.  Endocrine Soc (U.S.A.) Program Abstr 69th Annu Mtg  p. 572 (1987).
73. RENNIE, P.S., BRUCHOVSKY, N. and GOLDENBERG, S.L.:
Relationship of androgen receptors to the growth and regression of the prostate.  Eur J Cancer Clin Oncol  23:1248 (1987).
74. GOUT, P.W., BEER, C.T., DE JONG, G., RENNIE, P.S. and BRUCHOVSKY, N.:
Prolactin-induced generation of transferring-receptors: a critical event in the mitogenesis of lactogen - dependent Nb2 node rat lymphoma cells.  J Steroid Biochem  28:141S (1987).
75. LAWSON, D., BRUCHOVSKY, N., RENNIE, P.S., GOLDENBERG, S.L. and FLETCHER, T.:
Relative effectiveness of androgen withdrawal therapies as measured by changes in the intracellular distributions of androgen receptors and dihydrotestosterone.  J Steroid Biochem  28:11S (1987).
76. BRUCHOVSKY, N., GOLDENBERG, S.L., RENNIE, P.S., TO, M. and COPPIN, C.M.L.:
Mechanisms and effects of androgen withdrawal therapies.  J Steroid Biochem  28:195S (1987).
77. BRUCHOVSKY, N., RENNIE, P.S., GOLDENBERG, S.L. and COPPIN, C.M.L.:
Limitations of androgen withdrawal therapy of prostatic carcinoma - the next step?  Second Symp Prostate Cancer Program Abstr  p. 9 (1987).
78. BUTTYAN, R., SAWCZUK, I., BENSON, M., OLSSON, C., CONNOR, J., CHENG, H., RENNIE, P.S. and BRUCHOVSKY, N.:
Gene activity during regression of androgen - dependent tissues.  Proc Amer Assoc Cancer Res  29:239 (1988).
79. SNOEK, R., BRUCHOVSKY, N. and RENNIE, P.S.:
Purification of a 20,000 dalton protein associated with the nuclear androgen receptor.  Endocrine Soc (U.S.A.) Program Abstr 70th Annu Mtg  p. 93 (1988).
80. BRUCHVOSKY, N., RENNIE, P.S. and TO, M.:
The significance of stem cells in the evolution of androgen - independent malignancy.  8th Int Congr Endocrinol - Satellite Symp Sex Steroid-Dependent Tumors Abstr  p. 62 (1988).
81. RENNIE, P.S., BOWDEN, J.F., BRUCHOVSKY, N. and CHENG, H.:
Anti-plasminogen activator drugs inhibit the involution of rat ventral prostate.  8th Int Congr Endocrinol Abstr  p. 414 (1988).
82. BRUCHOVSKY, N., RENNIE, P.S., GOLDENBERG, S.L. and FLETCHER, T.:
Metabolic significance of stromal 5a-reductase activity in human prostate.  8th Int Congr Endocrinol Abstr  p. 423 (1988).
83. FREEMAN, S.N., RENNIE, P.S., BRUCHOVSKY, N., CHENG, H. and TENNISWOOD, M.:
Changes in gene expression in the rat ventral prostate gland following castration and treatment with cortisol.  Endocrine Soc (U.S.A.) Program Abstr 71st Annu Mtg  p. 367 (1989).
84. BRUCHOVSKY, N., RENNIE, P.S., COLDMAN, A.J., GOLDENBERG, S.L. and BOWDEN, M.:
Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma.  Amer Assoc Cancer Res Program Abstr 8th Annu Mtg  p. 295 (1989).
85. GOLDENBERG, S.L. and BRUCHOVSKY, N.:
Pre-suppression of the pituitary: an adjunct to LHRH agonist therapy of prostate cancer.  Amer Assoc Cancer Res Program Abstr 8th Annu Mtg  p. 309 (1989).
86. BRUCHOVSKY, N., GOLDENBERG, S.L., RENNIE, P.S. and COPPIN, C.M.L.:
Pre-suppression of the pituitary: an adjunct to LHRH agonist therapy of prostatic cancer.  Clin Invest Med  12:R-178 (1989).
87. BRUCHOVSKY, N., GOLDENBERG, S.L., RENNIE, P.S., COLDMAN, A.J. and BOWDEN, M.:
Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma.  Clin Invest Med  12:R-179 (1989).
88. BRUCHOVSKY, N.:
New approaches to the understanding of hormonal therapy of prostatic cancer.  Urol Oncol Today & Tomorrow Abstr Clin Program  p. 21 (1989).
89. ASASE, D., KATZ, A., WISE, G.J., OLSSON, C.A., BENSON, M.C., BUTTYAN, R., BRUCHOVSKY, N., CHENG, H. and RENNIE, P.S.:
Potential role for the multiple drug resistance P-glycoprotein in the development of androgen-independent prostate cancer.  Amer Urol Assoc 85th Annu Mtg Program Abstr  p. 204A (1990).
90. RENNIE, P.S. and BRUCHOVSKY, N.:
Activation of cell-death genes in tumorigenic stem cells of androgen-dependent malignancies.  Second Int Symp Hormonal Manipulation Cancer Program Abstr  p. 34 (1990).
91. OTAL, N.K., RENNIE, P.S., BRUCHOVSKY, N., GOLDENBERG, S.L. and TENNISWOOD, M.P.R.:
Isolation of androgen - repressed genes related to regression of the Shionogi mouse mammary carcinoma.  Amer Urol Assoc 86th Annu Mtg Program Abstr  p. 314A (1991).
92. AKAKURA, K., OTAL, N.K., RENNIE, P.S., GOLDENBERG, S.L. and GOLDENBERG, N.:
Effects of intermittent androgen - withdrawal therapy on the growth and progression of androgen-dependent tumours.  W Sect Amer Urol Assoc Program Abstr  p. 63 (1991).
93. BRUCHOVSKY, N., AKAKURA, K., RENNIE, P.S. and GOLDENBERG, S.L.:
Regulation of stem cells in androgen-dependent tumors.  Terra Symp Androgens Antiandrogens Program Abstr  p. 22.1 (1991).
94. MCQUEEN, S.A., SHEPPARD, P.C., CHENG, H., BRUCHOVSKY, N., RENNIE, P.S., CATTINI, P.A. and MATUSIK, R.J.:
Characterization of a DNA element that modulates activity of the androgen responsive element.  Soc Basic Urol Res Annu Mtg Abstr  (1991).
95. AKAKURA, K., BRUCHOVSKY, N., GOLDENBERG, S.L., RENNIE, P.S. and SULLIVAN, L.D.:
Preserved apoptotic potential during intermittent androgen withdrawal therapy in androgen dependent tumors.  Amer Urol Assoc 87th Annu Mtg Program Abstr  p. 453A (1992).
96. SNOEK, R., RENNIE, P.S., BRUCHOVSKY, N., CHENG, H., SHEPPARD, P.C. and MATUSIK, R.J.:
Binding of recombinant androgen receptor peptides to the 5' flanking DNA of the probasin gene.  Endocrine Soc (USA) Program Abstr 74th Annu Mtg  p. 428 (1992).
97. MCQUEEN, S.A., SHEPPARD, P.C., HAMEL, A., CHENG, H., SNOEK, R., BRUCHOVSKY, N., RENNIE, P.S. and MATUSIK, R.J.:
Characterization of two cis-acting DNA elements responsible for androgen regulation of the prostatic probasin gene.  Endocrine Soc (USA) Program Abstr 74th Annu Mtg  p. 428 (1992).
98. RENNIE, P.S., BRUCHOVSKY, N., SNOEK, R., CHENG, H., SHEPPARD, P.C., MCQUEEN, S. and MATUSIK, R.J.:
Two androgen response elements are necessary for androgen regulation of the probasin gene.  9th Int Congr Endocrinol Abstr  p. 534 (1992).
99. GOLDENBERG, S.L., BRUCHOVSKY, N., AKAKURA, K., TO, M. and RENNIE, P.S.:
PSA response to androgen withdrawal therapy: a predictor of survival.  W Sect Amer Urol Assoc Program Abstr  (1992).
100. BRUCHOVSKY, N., AKAKURA, K., GOLDENBERG, S.L. and RENNIE, P.S.:
Preservation of apoptotic potential in androgen-dependent tumors by intermittent androgen withdrawal.  J Cell Biochem  16D:Suppl:96 (1992)
101. MATUSIK, R.J., McQUEEN, S.A., SHEPPARD, P.C., KASPER, S., HOARE, S., CHENG, H, SNOEK, R., CATTINI, P.A., BRUCHOVSKY, N. and RENNIE, P.S.:
Androgen regulation of the prostatic probasin gene requires two cis-acting DNA elements.  Int Symp Biol Prostate Growth Abstr  p. 12 (1992).
102. RENNIE, P.S., BRUCHOVSKY, N., MATUSIK, R.J., GUSTAFSSON, J.A., DAHLMAN-WRIGHT, K. and DEDHAR, S.:
Interdependent action of glucocorticoid and androgen on the prostate.  Int Symp Biol Prostate Growth Abstr  30 (1992).
103. RENNIE, P.S., BRUCHOVSKY, N., SNOEK, R., SHEPPARD, P.C., GUSTAFSSON, J.-A., DAHLMAN-WRIGHT, K. and CHENG, H.:
Androgen and glucocorticoid receptors have different binding affinities for two hormonal responsive elements essential for hormonal induction of the probasin gene.  Endocrine Soc (U.S.A.) Program Abstr 75th Annu Mtg  p. 202 (1993).
104. SHEPPARD, P.C., KASPER, S., McQUEEN, S.A., HOARE, S., LIN, L., BRUCHOVSKY, N. and MATUSIK, R.J.:
Preferential androgen action on the prostatic probasin gene requires two androgen receptor binding sites plus adjacent DNA sequences.  Endocrine Soc (U.S.A.) Program Abstr 75th Annu Mtg  p. 203 (1993).
105. AKAKURA, K., BRUCHOVSKY, N., RENNIE, P.S., GOLDENBERG, S.L. and JONES, E.C.:
Significance of stromal expression of type 2 5a-reductase mRNA in benign prostatic hyperplasia.  Soc Basic Urol Res Annu Mtg Abstr  (1993).
106. AKAKURA, K., BRUCHOVSKY, N., RENNIE, P.S., GOLDENBERG, S.L., JONES, E.C., MAWIJ, N.M. and MAWIJ, N.R.:
Significance of stromal expression of type 2 5a-reductase mRNA in benign prostatic hyperplasia.  Clin Invest Med  16:Suppl:B43 (1993).
107. BRUCHOVSKY, N., AKAKURA, K., RENNIE, P.S. and GOLDENBERG, S.L.:
Adverse effects of androgen ablation on stem cells and clusterin synthesis in the Shionogi carcinoma.  Int Symp Fundamental Approach Diagnosis Treatment Prostate Cancer BPH Program Abstr  p. 17 (1993).
108. BRUCHOVSKY, N., AKAKURA, K., GOLDENBERG, S.L., GLEAVE, M.E., RENNIE, P.S. and SULLIVAN L.D.:
Intermittent androgen suppression in the treatment of prostate cancer.  Int Symp Fundamental Approach Diagnosis Treatment Prostate Cancer BPH Program Abstr  p. 35 (1993).
109. RENNIE, P.S., KASPER, S., BRUCHOVSKY, N., MATUSIK, R.J., SNOEK, R., SHEPPARD, P.C. and CHENG, H.:
Two hormone responsive elements, essential for androgen induction of the probasin gene, bind androgen receptors in a cooperative, mutually dependent fashion.  J Cell Biochem  18B:Suppl:371 (1994).
110. BRUCHOVSKY, N., AKAKURA, K., RENNIE, P.S., and SNOEK, R.:
Structure and function of androgen-receptor in androgen-independent malignancy.  J Cell Biochem  18B:Suppl:351 (1994).
111. BRUCHOVSKY, N., AKAKURA, K., RENNIE, P.S. and GOLDENBERG, S.L.:
Mechanisms of tumor progression during intermittent androgen suppression.  J Cell Biochem  18D:Suppl:251 (1994).
112. KRONGRAD, A., KASPER S., BAI, G., RENNIE, P.S., BRUCHOVSKY, N. and MATUSIK, R.J.:
Cis-DNA elements bind the androgen receptor and repress expression of the c-fos and ornithine decarboxylase genes.  Soc Basic Urol Res Annu Mtg Abstr  (1994).
113. GOUT, P.W., FOX, K., HORSMAN, D.E., DE JONG, G. and BRUCHOVSKY, N.:
Cultured rat Nb2 lymphoma cell lines provide a system for in vivo studies of progression of protein hormone-dependent, non-metastatic cancers to hormone independent growth and metastasis.  Endocrine Soc (U.S.A.) Program Abstr 76th Annu Mtg  p. 1026 (1994).
114. KASPER, S., RENNIE, P.S., BRUCHOVSKY, N., SHEPPARD, P.C., CHENG, H., LIN, L., SNOEK, R. and MATUSIK, R.J.:
Androgen specific regulation of the probasin gene is determined by two androgen receptor binding sites and the probasin promoter.  Endocrine Soc (U.S.A.) Program Abstr 76th Annu Mtg  p. 1214 (1994)
115. BRUCHOVSKY, N., S.L., AKAKURA, K., GLEAVE, M.E. and RENNIE, P.S.:
Hormonal therapy for prostate cancer.  Urol Soc Australasia 47th Annu Sci Mtg Abstr  p. 27 (1994).
116. BRUCHOVSKY, N., AKAKURA, K. and RENNIE, P.S.:
Experimental basis for intermittent androgen suppression of prostate cancer.  Urol Soc Australasia 47th Annu Sci Mtg Abstr  p. 96 (1994).
117. GOLDENBERG, S.L., BRUCHOVSKY, N., GLEAVE, M.E., SULLIVAN L.D. and AKAKURA, K.:
Intermittent androgen suppression in the treatment of prostate cancer.  J Urol  151: 204A (1994).
118. SULLIVAN L.D., GLEAVE, M.E., GOLDENBERG, S.L., BRUCHOVSKY, N. and JONES, E.C.:
Long - term neoadjuvant hormone therapy prior to radical prostatectomy in localized prostate cancer.  J Urol  151: 435A (1994).
119. GLEAVE, M.E., BRUCHOVSKY, N., BOWDEN, M., GOLDENBERG, S.L. and SULLIVAN L.D.:
Intermittent androgen suppression prolongs time to androgen-independent progression in the LNCaP prostate tumor model.  J Urol  151: 457A (1994).
120. GLEAVE, M.E., BOWDEN, M., BRUCHOVSKY, N., GOLDENBERG, S.L. and SULLIVAN L.:
Predictors of time to androgen-independent progression in the LNCaP prostate tumor model.  J Urol  151: 458A (1994).
121. BRUCHOVSKY, N., AKAKURA, K., RENNIE, P.S., GOLDENBERG, S.L. and GLEAVE, M.E.:
Cell death in the Shionogi mammary carcinoma: a model for treatment of hormone-dependent cancers.  Tenth Int Symp Cell Endocrinol Program Abstr  p. 63 (1994).
122. BRUCHOVSKY, N., AKAKURA, K., RENNIE, P.S., GOLDENBERG, S.L. and GLEAVE, M.E.:
Adaptation and tumor progression after androgen ablation.  Soc Basic Urologic Res Fall Symp Program Abstr  p. 16 (1994).
123. RENNIE, P.S., KASPER, S., BRUCHOVSKY, N., CHENG, H., MATUSIK, R. and SNOEK, R.:
Androgen receptor interactions.  Soc Basic Urologic Res Fall Symp Program Abstr  p. 21 (1994).
124. BRUCHOVSKY, N., GOLDENBERG, S.L., AKAKURA, K., GLEAVE, M.E. and RENNIE, P.S.:
Intermittent androgen blockade therapy in prostate cancer.  Cancer Invest  13:Suppl 1:46 (1994).
125. SATO, N., GLEAVE, M.E., RENNIE, P.S., GOLDENBERG, S.L., BRUCHOVSKY, N. and SULLIVAN, L.D.:
Intermittent androgen suppression delays progression to androgen-independent state in human prostate cancer, LNCaP tumor model.  Can J Urol  2(3):A38 (1995).
126. GLEAVE, M.E., GOLDENBERG, S.L., BRUCHOVSKY, N., JONES, E.C. and SULLIVAN, L.D.:
Biochemical and pathological effects of eight months of neoadjuvant hormone therapy prior to radical prostatectomy in clinically confined prostate cancer.  Can J Urol  2(3):A67 (1995).
127. SATO, N., GLEAVE, M.E., GOLDENBERG, S.L., BRUCHOVSKY, N., RENNIE, P.S. and SULLIVAN, L.D.:
Intermittent androgen suppression delays time to androgen-independent progression in the LNCaP prostate tumour model.  J Urol  153(4):282A (1995).
128. GLEAVE, M.E., GOLDENBERG, S.L., JONES, E.C., BRUCHOVSKY, N. and SULLIVAN, L.D.:
Maximal biochemical and pathological down staging requires 8 months of neoadjuvant hormonal therapy prior to radical prostatectomy.  J Urol  153(4):392A (1995).
129. GOLDENBERG, S.L., BRUCHOVSKY, N., GLEAVE, M.E. and SULLIVAN, L.D.:
Intermittent androgen suppression in the treatment of prostate cancer.  J Urol  153(4):448A (1995).
130. GOLDENBERG, S.L., BRUCHOVSKY, N., GLEAVE, M.E. and SULLIVAN, L.D.:
Intermittent androgen suppression in the treatment of prostate carcinoma.  Can J Urol  2(3):A67 (1995).
131. BRUCHOVSKY, N., RENNIE, P.S., GOLDENBERG, S.L. and GLEAVE, M.E.:
Mechanisms of prostatic tumor progression and maintenance of androgen dependence.  Int Conf Androgenic Hormones, Prostate Cancer Benign Prostatic Hyperplasia, Program Abstr  (1995).
132. BRUCHOVSKY, N., SNOEK, R., RENNIE P.S., DEDHAR, S. and CHENG, H.:
Calreticulin and clusterin: two proteins with possible nuclear functions that are implicated in the regulation of the early and late stages of apoptosis.  Int Conf Androgenic Hormones, Prostate Cancer Benign Prostatic Hyperplasia, Program Abstr  (1995).
133. SATO, N., RENNIE, P.S., GOLDENBERG, L., BRUCHOVSKY, N. and GLEAVE, M.E.:
Intermittent androgen suppression prolongs time to androgen-independent progression in the LNCaP prostate tumor model.  Int Conf Androgenic Hormones, Prostate Cancer Benign Prostatic Hyperplasia, Program Abstr  (1995).
134. SNOEK, R., MAWJI, N.R., RENNIE, P.S. and BRUCHOVSKY, N.:
Transcriptional modulation by the N-terminal domain of the androgen receptor.  Int Conf Androgenic Hormones, Prostate Cancer Benign Prostatic Hyperplasia, Program Abstr  (1995).
135. CHENG, H., RENNIE, P.S., KASPER, S., MATUSIK, R., SNOEK, R. and BRUCHOVSKY, N.:
Androgen and glucocorticoid receptor interactions with probasin AREs.  Int Conf Androgenic Hormones, Prostate Cancer Benign Prostatic Hyperplasia, Program Abstr  (1995).
136. BRUCHOVSKY, N., AKAKURA, K., RENNIE, P.S., GOLDENBERG, S.L. and GLEAVE, M.E.:
The 3R's (reductase, receptor, response element) of androgen action: basis of a novel therapy for prostate cancer. Japanese Urological Association 83rd Annual Meeting Program and Abstracts. Nippon Hinyokika Gakkai Zasshi.  Jap J Urol  86(3):348 (1995).
137. SATO, N., BRUCHOVSKY, N., GLEAVE, M.E., RENNIE, P.S., SADAR, M.D. and SATO, S.:
Androgenic induction of prostate specific antigen gene is suppressed by direct protein-protein interaction between the androgen receptor and c-Jun or c-Fos in the human prostate cancer cell line LNCaP.  Amer Urol Assoc 91st Annu Mtg Program Abstr  (1995).
138. GOUT, P.W., KANG, Y.J., BUCKLEY, D.J., BRUCHOVSKY, N. and BUCKLEY, A.R.:
Change in thiol growth requirement in the malignant progression of Nb2 lymphoma cells.  Amer Assoc Cancer Res 87th Annu Mtg Program Abstr  p. 37 (1996)
139. GLEAVE, M.E., GOLDENBERG, S.L., JONES, E.C., BRUCHOVSKY, N. and SULLIVAN, L.D.:
Biochemical and pathological effects of eight months of neoadjuvant androgen withdrawal therapy prior to radical prostatectomy in clinically confined prostate cancer.  Cancer Invest  14:49-51 (1996).
140. GLEAVE, M.E., SATO, N., GOLDENBERG, S.L., BRUCHOVSKY, N. and SULLIVAN, L.D.:
Neoadjuvant androgen ablation reduces local recurrence rates after tumour excision in the androgen-dependent Shionogi tumour model.  J Urol  155(49):323A (1996).
141. SATO, N., GLEAVE, M.E., BRUCHOVSKY, N., RENNIE, P.S., GOLDENBERG, S.L. and SULLIVAN, L.D.:
A metastatic and androgen - sensitive human prostate cancer animal model using orthotopic inoculation of LNCaP cells in SCID mic.  J Urol  155(109):338A (1996).
142. SADAR, M.D., BRUCHOVSKY, N., AKUKURA, K., RENNIE, P.S. and GOLDENBERG, S.L.:
Characterization of 5?-reductase gene expression in benign prostate hyperplasia and human prostate cell lines.  10th Int Congr Endocrinol Program Abstr  (1996).
143. GOLDENBERG, S.L., BRUCHOVSKY, N., GLEAVE, M.E. and SULLIVAN, L.D.:
Intermittent androgen suppression in the treatment of prostatic carcinoma: an update. Amer Urol Assoc 92nd Annu Mtg Program Abstr  J Urol  147(4):333 (1997).
144. GLEAVE, M.E., GOLDENBERG, S.L., JONES, E., BRUCHOVSKY, N. and SULLIVAN, L.D.:
Biochemical and pathological effects of eight months of neoadjuvant androgen withdrawal therapy - and update on 125 consecutive patients. Amer Urol Assoc 92nd Annu Mtg Program Abstr  J Urol  147(4):390 (1997).
145. SADAR, M.D., SATO, N., BRUCHOVSKY, N., SAATICIOGLU, F., RENNIE, P.S., SATO, S., LANGE, P.H. and GLEAVE, M.E.:
The role of AP-1 in prostate tumour progression. Roy Coll Phys Surg Can Annu Mtg Program Abstr  Clin Invest Med  20(4):95 (1997).
146. RENNIE, P.S., SNOEK, R., BRUCHOVSKY, N., KASPER, S., MATUSIK, R.J., GLEAVE, M.E., SATO, N. and MAWJI, N.R.:
Differential gene induction in prostate cancer cells by AF-1 and AF-2 of the androgen receptor. Roy Coll Phys Surg Can Annu Mtg Program Abstr  Clin Invest Med  2(4):96 (1997).
147. SNOEK, R., BRUCHOVSKY, N., SADAR, M.D. and RENNIE, P.S.:
PSA promoter induction of RNA in a cell-free in vitro transcription assay.  Roy Coll Phys Surg Can Annu Mtg Program Abstr Clin Invest Med  2(4):101 (1997).
148. BRUCHOVSKY, N., KLOTZ, L., CROOK, J., ARMITAGE, G., GLEAVE, M.E. and GOLDENGERG, S.L.:
A phase II study of intermittent androgen suppression in men with a rising serum PSA after radiation for localized prostate cancer. Roy Coll Phys Surg Can Annu Mtg Program Abstr  Clin Invest Med  2(4):378 (1997).
149. BERALDI, E., BRUCHOVSKY, N., GLEAVE, M.E., GOLDENBERG, S.L. and RENNIE, P.S.:
Clinical use of nested RT-PCR for PSA during the treatment of prostate cancer by androgen withdrawal therapy. Roy Coll Phys Surg Can Annu Mtg Program Abstr  Clin Invest Med  2(4):384 (1997).
150. GOLDENBERG, S.L., BRUCHOVSKY, N., GLEAVE, M.E. and SULLIVAN, L.D.:
Intermittent androgen suppression in the treatment of prostatic carcinoma: An update.  J Urol  157(4):390 (1997).
151. GLEAVE, M.E., GOLDENBERG, S.L., JONES, E.C., BRUCHOVSKY, N. and SULLIVAN, L.D.:
Biochemical and pathological effects of eight months of neoadjuvant androgen withdrawal therapy - an update on 125 consecutive patients.  Can J Urol  4(2):322 (1997).
152. GOLDENBERG, S.L., BRUCHOVSKY, N., GLEAVE, M.E. and SULLIVAN, L.D.:
Failure of radical radiation: Is intermittent androgen suppression an option?  Can J Urol  4(2):327 (1997).
153. SATO, N., GLEAVE, M.E., BRUCHOVSKY, N., RENNIE, P.S., BERALDI, E. and SULLIVAN, L.D.:
A metastatic and androgen-sensitive human prostate cancer model using intraprostatic inoculation of LNCaP cells in SCID mice.  Br J Urol  80(2):238 (1997).
154. GLEAVE, M.E., GOLDENBERG, S.L., JONES, E.C., BRUCHOVSKY, N. and SULLIVAN, L.D.:
Biochemical and pathological effects of eight months of neoadjuvant androgen withdrawal therapy - an update on 125 consecutive patients.  Br J Urol  80(2):202 (1997).
155. GLEAVE, M.E., GOLDENBERG, S.L., JONES, E.C., BRUCHOVSKY, N. and SULLIVAN, L.D.:
Biochemical and pathological effects of eight months of neoadjuvant androgen withdrawal therapy - an update on 125 consecutive patients.  W Sect Amer Urol Assoc 73rd Annu Mtg Program Abstr  p. 179 (1997).
156. GOLDENBERG, S.L., BRUCHOVSKY, N., GLEAVE, M.E. and SULLIVAN, L.D.:
Intermittent androgen suppression in the treatment of prostatic carcinoma: an update.  W Sect Amer Urol Assoc 73rd Annu Mtg Program Abstr  p. 184 (1997).
157. RENNIE, P.S., GOLDENBERG, S.L., BRUCHOVSKY, N. and GLEAVE, M.E.:
Intermittent androgen suppression in the treatment of prostatic carcinoma: an update.  5th SPORE Invest Workshop  p.11 (1997).
158. SNOEK, R., SADAR, M.D., RENNIE, P.S., NELSON, C. and BRUCHOVSKY, N.:
PSA promoter activity is repressed in PC3 cells compared to LNCaP cells.  5th SPORE Invest Workshop  (1997).
159. SADAR, M.D., MAWJI, N.R. and BRUCHOVSKY, N.
Androgen - Independent. Induction of Prostate Specific Antigen Gen Expression, Via Cross - Talk Between the Androgen Receptor and PKA Signal Transduction Pathways.  2nd World Congr Urol Res  (1997).
160. BRUCHOVSKY, N., KLOTZ, L.H., CROOK, J.M., ARMITAGE, G.R., GLEAVE, M.E. and GOLDENBERG, S.L.:
A phase II study of intermittent androgen suppression (IAS) in men with a rising serum PSA after radiation for localized prostate cancer.  J Urol  159:335 (1998).
161. SADAR, M.D., BRUCHOVSKY, N. and MAWJI, N.R.:
Increased expression of the prostate specific antigen gene via ligand - independent activation of the androgen receptor.  Amer Urol Assoc W Sect 74th Annu Mtg Abstr  p. 146 (1998).
162. SADAR, M.D. and BRUCHOVSKY, N.:
Increased expression of the prostate specific antigen gene via ligand-independent activation of the androgen receptor.  6th SPORE Invest Workshop  (1998).
163. BRUCHOVSKY, N.:
Intermittent endocrine therapy for prostate cancer.  Progr Controversies Oncol Urol V (PACIOU V) An Update on Renal, Bladder and Prostate Cancer Abstr  pp. 44-45 (1998).
164. BRUCHOVSKY, N.:
Intermittent androgen suppression for patients failing radiation therapy with a rising PSA: background and recent experience.  Chemotherap Found Symp XVI Innovative Cancer Therapy for Tomorrow Abstr  pp. 58-62 (1998).
165. BRUCHOVSKY, N.:
Androgen biochemistry.  2nd Int Consult Prostate Cancer  (1999).
166. SADAR, M.D., BRUCHOVSKY, N., MAWJI, N. and GLEAVE, M.:
Ligand-independent activation of the human androgen receptor by butyrate in human prostate cancer cells.  7th SPORE Invest Workshop Abstr  p. 67 (1999).
167. UEDA, T., BRUCHOVSKY, N., SNOEK, R. and SADAR, M.D.:
Interleukin-6 regulates the prostate-specific antigen gene promoter by activation of the amino-terminal domain of the human androgen receptor. Amer Urol Assoc 95th Annu Mtg Program Abstr  J Urol  p. 97 (April 2000).
168. UEDA, T., BRUCHOVSKY, N., SNOEK, R. and SADAR, M.D.:
Interleukin-6 regulates the prostate-specific antigen gene promoter by activation of the amino-terminal domain of the human androgen receptor.  3rd Asian and Oceanic Congr Androl  (May 2000).
169. KIM, TS-Y, FOX, K., MAWJI, N.R., HARE, H.A., SCHWEIKERT, H.U. and SCHNABEL, D.D.:
McAlinden GM, Duncan CP, Jones EC, BRUCHOVSKY N, Sadar MD. Androgen-independent activation of the PSA gene by factors secreted from osteoblast-like cells.  Bridging Strait Georgia 5th Symp Cancer Res  (May 2000).
170. MAWJI, N.R., BRUCHOVSKY, N., MENDELEV, N., GOUT, P.W. and SADAR, M.D.:
Androgen-independent increases in prostate-specific antigen gene expression can be inhibited by peptides mimicking sections of the amino-terminus of the androgen receptor.  Bridging Strait Georgia 5th Symp Cancer Res  (May 2000).
171. UEDA, T., BRUCHOVSKY, N., MAWJI, N.R., HARE, H.A., SNOEK, R. and SADAR, M.D.:
Interleukin-6 regulates the prostate-specific antigen gene promoter by activation of the amino-terminal domain of the human androgen receptor.  Bridging Strait Georgia 5th Symp Cancer Res  (May 2000).
172. UEDA, T., BRUCHOVSKY, N., MAWJI, N.R., HARE, H.A., SNOEK, R. and SADAR, M.D.:
Interleukin-6 regulates the prostate-specific antigen gene promoter by activation of the amino-terminal domain of the human androgen receptor.  8th SPORE Invest Workshop  p.85 (July 2000).
173. GOUT, P.W., BUCKLEY, A.R., SIMMS, C.R., and BRUCHOVSKY, N.:
Novel lymphoma growth-inhibitory activity of the immunosuppressant sulfasalazine (SASP).  11th Int Congr Endocrinol (ICE2000)  p. 310 (Oct. 2000).
174. SADAR, M.D., BRUCHOVSKY, N., GOUT, P.W., SNOEK, R., and MAWJI, N.R.,:
Androgen-independent increases in the expression of prostate-specific antigen can be inhibited by peptides mimicking sections of the N-terminus of the androgen receptor.  11th Int Congr Endocrinol (ICE2000)  p. 310 (Oct. 2000).
175. KIM, TS-Y, BRUCHOVSKY, N., MCALINDEN, G.M., DUNCAN, C.P., EDWARD, C.J., SCHNABEL, D.D., SCHWEIKERT, H.U. and SADAR, M.D.:
Androgen-independent activation of the PSA gene by factors secreted from osteoblast-like cells.  9th Annu Soc for Basic Urol Res (SBUR) Fall Symp P863  p. 8 (Nov. 2000).
176. AKOPIAN, V., BRUCHOVSKY, N., BERALDI, E., SIGNAEVSKY, M. and SADAR, M.D.:
Characterization of a new in vivo prostate tumor model.  9th Annu Soc Basic Urol Res (SBUR) Fall Symp  p.1 (Nov. 2000).
177. UEDA, T., BRUCHOVSKY, N. and SADAR, M.D.:
Activation of the N-terminus domain of the human androgen receptor by interleukin-6 is mediated through MAP kinase and Stat3 signal transduction pathways in prostate cancer cells.  9th Annu Soc Basic Urol Res (SBUR) Fall Symp  p. 22 (Nov. 2000).
178. BRUCHOVSKY, N., GOUT, P.W., SNOEK, R., MAWJI, N.R. and SADAR, M.D.:
Targeting the N-terminus of the androgen receptor for therapeutic intervention of androgen-independent prostate cancer.  Mol Biol New Therap Strat: Cancer Res 21st Cent  (2001).
179. UEDA, T., BRUCHOVSKY, N., KIM, T.S.Y., and SADAR, M.D.:
Ligand-independent activation of the androgen receptor and the role of the coactivator SRC-1A in prostate cancer cells.  J Androl  May/June supplement:199 (2001).
180. BRUCHOVSKY, N.:
Intermittent androgen suppression (IAS) in the treatment of prostate cancer.  J Androl  May/June supplement:149 (2001).
181. UEDA, T., KIM, T.S.Y., BRUCHOVSKY, N.and SADAR, M.D.:
Ligand-independent activation of the androgen and the role of the coactivator SRC-1a in prostate cancer cells.  9th SPORE Invest Workshop  (2001).
182.

BRUCHOVSKY, N. Intermittent androgen sup pre ssion: Rationale for an Innovative Approach to Androgen Deprivation Therapy. The Endocrine Soc ( U.S.A. ) Program Abstr 90 th Annu Mtg p. 35 (2008).

183.

HIGANO, C.S., HIRATA, Y., AKAKURA, K., BRUCHOVSKY, N., AIHARA, K. Retrospective mathematical analysis of serial prostate specific antigen (PSA) measurements for patients with M0 prostate cancer treated with intermittent androgen suppression (IAS). ASCO Abstracts #100884 (2012).

Other Papers and Speaking Engagements

1. Control of the Concentration and Distribution of Dihydrotestosterone in Prostate Cells. International Symposium on Normal and Abnormal Growth of Prostate, San Antonio, Texas, USA, 1973.
2. The Influence of Androgen Receptors on the Concentration of Androgens in Nuclei of Hormone Responsive Cells. Fourth International Congress on Hormonal Steroids, Mexico City, Mexico, 1974.
3. Androgen Receptors in Normal and Neoplastic Tissues. Symposium on Hormone Receptors. Canadian Society for Clinical Investigation and the Royal College of Physicians and Surgeons, Winnipeg, Manitoba, 1975.
4. Androgen Receptors in Normal and Neoplastic Cells. McGill University, Montreal, Quebec, 1975.
5. Hormonal Effects on Cell Proliferation in Rat Prostate. International Symposium in Honour of Dr. Charles B. Huggins, Helsingborg, Sweden, 1975.
6. The Effect of Steroid Hormones on Proliferative Growth. Symposium on the Control of Differentiated Function in Eukaryotic Cells, Banff, Alberta, 1975.
7. Does 5a-Dihydrotestosterone Cause Benign Prostatic Hyperplasia? Canadian Urological Society, Jasper, Alberta, 1975.
8. Steroid Receptor Proteins and Regulation of Growth in Mammary Carcinoma. National Conference on Breast Cancer, Montreal, Quebec, 1975.
9. Receptor Proteins in Tumours. Seventh Congress of the International Study Group for Steroid Hormones, Rome, Italy, 1975.
10. Relationship between Hormone Receptors and Responsiveness of Cells. Karolinska Institute, Stockholm, Sweden, 1975.
11. Relationship between Hormone Receptors and Responsiveness of Cells. Universitats - Krankenhaus Eppendorf, Hamburg, West Germany, 1975.
12. Relationship between Hormone Receptors and Responsiveness of Normal and Neoplastic Cells. University of Calgary, Calgary, Alberta, 1976.
13. Relationship between Hormone Receptors and Responsiveness of Normal and Neoplastic Cells. University of Western Ontario, 1976.
14. Clinical Studies with Receptors. Annual Symposium, Cancer Control Agency of British Columbia, Vancouver, British Columbia, 1976.
15. New Concepts in the Management of Hormone-Sensitive Malignancies. National Cancer Institute of Canada, Workshop on Chemotherapy, Winnipeg, Manitoba, 1976.
16. Mechanism of Action of Androgens. Johns Hopkins University, Baltimore, USA, 1976.
17. Steroid Hormones and Tumours of the Male Reproductive Tract. Symposium on Hormones and Cancer, Royal College of Physicians and Surgeons, Toronto, Ontario, 1977.
18. Hormonal Control of Neoplastic Growth. Cancer Control Agency of British Columbia, Annual General Meeting, Vancouver, British Columbia, 1977.
19. Pathological Growth of Androgen Sensitive Tissues Resulting From Latent Actions of Steroid Hormones. National Center for Toxicological Research Fourth Annual Hormone Research Symposium, Jefferson, USA, 1977.
20. Predictive Markers of Androgen Action in Normal, Hyperplastic and Neoplastic Human Prostates. First Innsbruck Winter Conference on Biochemistry in Clinical Medicine, Innsbruck-Igls, Austria, 1978.
21. A. Mechanism of Action of Androgens. B. A New Approach to the Hormonal Therapy of Mammary and Prostatic Cancers. Katholieke Universiteit, Nijmegen, The Netherlands, 1978.
22. Markers of Androgen Action in Normal, Hyperplastic and Neoplastic Human Prostates: Clinical Applications. Erasmus Universiteit, Rotterdam, The Netherlands, 1978.
23. The Control of Prostatic Growth by Alterations in Hormonal Balance. Royal Infirmary, Glasgow, United Kingdom, 1978.
24. A. Steroid Receptors and the Regulation of DNA replication.
B. Considerations in the Hormonal Induction and Regulation of Animal Tumours. UICC Prostatic Cancer Workshop, Geneva, Switzerland, 1978.
25. A. Estrogen Receptors in Endometrial Carcinoma.
B. Hormonal Treatment of Endometrial Carcinoma. D.A. Boyes Society, Fourth Annual Meeting, Vancouver, British Columbia, 1978.
26. Endocrine Therapy and the Theoretical Basic Responses of Neoplasms. Institut du Cancer de Montreal, Montreal, Quebec, 1979.
27. Molecular Action of Androgens and Antiandrogens. Symposium uber Androgenisierungserscheinungen bei der Frau, Schering AG, Berlin, 1979.
28. New Aspects of Androgen Action in the Prostate: Stromal Localization of 5a - Reductase, Nuclear Abundance of Dihydrotestosterone and Binding of Receptor to Linker DNA. Workshop of the Society of Urologic Oncology and Endocrinology, Amsterdam, The Netherlands, 1979.
29. New Aspects of Androgen Action in the Prostate. Lady Davis Institute for Medical Research, Montreal, Quebec, 1979.
30. Mechanism of Action of Androgens and Antiandrogens. Hopital Maisonneuve-Rosemont, Universite de Montreal, Montreal, Quebec, 1979.
31. Cellular Factors Contributing to the Concentration of Dihydrotestosterone by Hyperplastic and Carcinomatous Human Prostates. First International Congress on Hormones and Cancer, Rome, Italy, 1979.
32. Hormone Receptors in Prostatic Tissue. Ninth Congress of the International Study Group for Steroid Hormones, Rome, Italy, 1979.
33. Rationale for the Use of Steroid Receptors in the Adjuvant Hormonal Therapy of Breast Cancer. Symposium on Management of Early Breast Cancer, Royal College of Physicians and Surgeons, Ottawa, Ontario, 1980.
34. Hormones and Cancer. Second Course in Oncology, National Cancer Institute of Canada, Hamilton, Ontario, 1980.
35. Endocrine Therapy of Prostatic Cancer. Advances in Oncology, Vancouver, British Columbia, 1980.
36. Androgen Metabolism in Stroma and Epithelium of Prostate and Epididymis. National Prostatic Cancer Project, Buffalo, New York, USA, 1981.
37. Cell Receptors, Their Role in Managing Endocrine Related Cancers. Scientific Advances in Diagnosis and Treatment, Saskatoon, Saskatchewan, 1981.
38. Rationale for the Use of Anti-hormone and Drug Combinations in the Treatment of Prostatic Carcinoma. International Symposium on Androgens and Anti-Androgens Utrecht, The Netherlands, 1982.
39. Stromal and Epithelial Contributions to the Metabolism of Testosterone in the Rat Ventral Prostate and Epididymis. Second Meeting of the European Society for Urological Oncology and Endocrinology, Stockholm, Sweden, 1982.
40. Steroid Hormone Receptors in Endocrine-Related Cancer. Symposium on Clinical Implications of Receptor Pharmacology, Canadian Society for Clinical Investigation, Quebec, Quebec, 1982.
41. Molecular Action of Cyproterone Acetate. Symposium on Pharmacological and Clinical Effects of Cyproterone Acetate Alone or in Combination with Ethinyl Estradiol, Montreal, Quebec, 1982.
42. Mechanisms of Androgen Regulation in Normal and Abnormal Prostate. Canadian Investigators in Reproduction, 13th Annual Meeting, Vancouver, British Columbia, 1983.
43. Carcinoma of the Prostate. Canadian Urological Association, 38th Annual Meeting, Victoria, British Columbia, 1983.
44. Hormonal Mechanisms in the Pathogenesis of Benign Prostatic Hyperplasia. Ontario Cancer Institute 25th Anniversary Research Day, Toronto, Ontario, 1983.
45. Androgens, BPH and Prostatic Carcinoma. 1984 CSLT National Congress, Vancouver, British Columbia, 1984.
46. Regulation of 5a-Reductase Activity in Stroma and Epithelium of Human Prostate. International Symposium on Regulation of Androgen Action, Montreal, Quebec, 1984.
47. A. Biologic and Phenotypic Changes During Regression and Recurrence of the Shionogi carcinoma. B. Regulation of Androgen Metabolism in the Human Prostate. Stanford University, School of Medicine, 13th Annual Symposium on Prostatic Carcinoma, New Frontiers, Palo Alto, USA, 1985.
48. Androgen Metabolism and Antiandrogens in BPH and Prostatic Cancer. Sterling-Winthrop Research Institute, Rensselaer, USA, 1985.
49. A. Endocrinology of Tumor Regression: Antiandrogens in Treatment of Prostate Cancer.
B. Regulation of Androgen Action. University of North Carolina, Chapel Hill, USA, 1985.
50. Endocrinology of Tumor Progression. Symposium on Endocrine Related Tumours: Facts and Controversies, Noordwijkerhout, The Netherlands, 1985.
51. Purification of Nuclear Androgen Receptor and Receptor-Acceptor Complexes. Workshop on Methodology of Nuclear Steroid Hormone Receptor Determinations, Noordwijerhout, The Netherlands, 1985.
52. Antiandrogens and 5a-Reductase Inhibition. University of Hamburg, Hamburg, Federal Republic of Germany, 1985.
53. Rationale for the Use of Cyproterone Acetate and Mini-Dose Diethylstilbestrol in the Treatment of Advanced Prostatic Cancer. Symposium on the Molecular Biology of the Prostate and Its Relationship to Prostate Diseases, Canadian Federation of Biological Societies 28th Annual Meeting, Toronto, Ontario, 1985.
54. Tumor Progression and Treatment. OSCC Prostate Cancer Program Workshop on Assessment of Current Concepts and Approaches to the Study of Prostatic Cancer, Prouts Neck, Maine, USA, 1985.
55. Regulation of Androgen Action in Normal and Abnormal Prostate. Terry Fox Course in Basic Sciences of Oncology, Ontario Cancer Institute, Toronto, Ontario, 1985.
56. Synergistic Hormonal Combinations in the Treatment of Prostatic Carcinoma. Grand Rounds, Princess Margaret Hospital, Toronto, Ontario, 1985.
57. New Hormonal Therapies of Prostatic Cancer. B.C. Society of Medical Oncology, Vancouver, British Columbia, 1986.
58. Treatment and Endocrinology of Prostate Tumor Progression. Dr. Daniel Den Hoed Kliniek Rotterdamsch Radio-Therapeutisch Instituut, Rotterdam, The Netherlands, 1986.
59. Androgens and Prostatic Carcinoma. Katholieke Universiteit Nijmegen, Nijmegen, The Netherlands, 1986.
60. Endocrinology and Treatment of Prostate Tumor Progression. Danish Urological Society, Copenhagen, Denmark, 1986.
61. Prostatic Cancer: Recent Advances in Treatment. Fourth Oncology Symposium on Vancouver Island, Victoria, British Columbia, 1986.
62. Adverse Effects of Androgen Withdrawal Therapy on the Shionogi Animal Model of Prostatic Carcinoma. OSCC Prostate Cancer Program Workshop on A Multidisciplinary Analysis of Controversies in the Management of Prostate Cancer, Prouts Neck, Maine, USA, 1986.
63. Pros and Cons of Androgen Withdrawal Therapy. B. C. Urological Association Annual Meeting, Vancouver, British Columbia, 1987.
64. A. Pharmacological Comparison of Available Drugs in the Treatment of Prostatic Cancer. B. Hormonal Treatment of Prostatic Cancer: Current Concepts. Symposium on Prostatic Cancer: Current Practices and New Therapies, Vancouver, British Columbia, 1987.
65. Mechanisms and Effects of Androgen Withdrawal Therapies. The Third International Congress on Hormones and Cancer Satellite Symposium on Prostate Cancer: Rationale of Endocrine Management, Hamburg, Federal Republic of Germany, 1987.
66. Limitations of Androgen Withdrawal Therapy of Prostatic Carcinoma - The Next Step? The Second Tokyo Symposium on Prostate Cancer, Tokyo, Japan, 1987.
67. Effects of Androgen Withdrawal on the Shionogi Carcinoma. Division of Biochemical Pharmacology, Shionogi Research Laboratories, Shionogi & Co. Ltd., Fukushima-ku, Osaka, Japan, 1987.
68. Mechanism of Action of Androgens and Anti-Androgens. Department of Urology, School of Medicine, Chiba University, Inohana, Chiba-shi, Japan, 1987.
69. The Significance of Stem Cells in the Evolution of Androgen-Independent Malignancy. Department of Pathology, University of Colorado Health Sciences Center, Denver, Colorado, USA, 1988.
70. Androgenic Action in Prostatic Tissue. Symposium on Cell - and Molecular Biology Aspects of Clinical Chemistry zur Verabschiedung von Prof. K. D. Voigt. Universitatskrankenhaus Hamburg- Eppendorf, Federal Republic of Germany, 1988.
71. Limitations of Androgen Withdrawal Therapy of Prostate Cancer - The Next Step? Danish Urologic Society Annual Meeting, Copenhagen, Denmark, 1988.
72. The Significance of Stem Cells in the Evolution of Androgen-Independent Malignancy. Department of Medical Nutrition, Karolinska Institute, Stockholm, Sweden, 1988.
73. New Concepts of Androgen Withdrawal Therapies in Prostatic Carcinoma. Department of Clinical Urology, Johann-Wolfgang-Goethe-Universitat, Frankfurt,am Main, Federal Republic of Germany, 1988.
74. Second Line Hormone Therapy. Symposium - An Update on Prostate Cancer Therapy, Vancouver, British Columbia, 1988.
75. The Significance of Stem Cells in the Evolution of Androgen-Independent Malignancy. 8th International Congress of Endocrinology - Satellite Symposium on Sex Steroid-Dependent Tumors, Tokyo, Japan, 1988.
76. Significance of Stem Cells in the Evolution of Androgen Independent Malignancy. Lady Davis Institute for Medical Research, Montréal, Québec, 1988.
77. Mechanism of Action of Androgens and Anti-Androgens. Hopital Saint-Francois D'Assise, Québec City, Québec, 1988.
78. New Approaches to the Understanding of Hormonal Therapy of Prostatic Cancer. Symposium on Urologic Oncology Today & Tomorrow, Toronto, Ontario, 1989.
79. Benign Prostatic Hyperplasia: Role of Androgens in Etiology - Physiologic and Mechanistic Data. Workshop Conference on Androgen Therapy: Biologic and Clinical Consequences, Marco Island, Florida, USA, 1990.
80. Antiandrogens in the Treatment of Advanced Prostate Cancer. Division of Urology, University of Viennna, Vienna, Austria, 1990.
81. New Indications for Antiandrogens in the Treatment of Prostate Cancer. Institute for Hormone and Fertility Research, Hamburg, Germany, 1990.
82. Hormone Management of Prostate Cancer. The Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, USA, 1991.
83. Control of Stem Cells in Androgen Dependent Tumors. University of Wisconsin Clinical Cancer Center, Madison, Wisconsin, USA 1991.
84. Control of Stem Cells in Androgen Dependent Tumors. Tufts University School of Medicine, Boston, Massachusetts, USA, 1991.
85. Regulation of Stem Cells in Androgen Dependent Tumors. Terra Symposium on Androgens and Antiandrogens, Mohonk Mountain House, New Paltz, New York, USA, 1991.
86. Maintenance of Apoptotic Potential in Androgen-Dependent Tumors by Intermittent Androgen Withdrawal. University of Washington School of Medicine, Seattle, Washington, USA, 1991.
87. Male Sex Hormones - from A to Z. University of British Columbia, Faculty of Medicine, Distinguished Medical Research Lecture, Vancouver, British Columbia, 1991.
88. A. Intermittent Androgen Withdrawal Therapy of Prostate Carcinoma.
B. Management of Hormone Resistant (Stage D3) Prostatic Carcinoma. Second International Prostate Cancer Update, Vail/Beaver Creek, Colorado, USA, 1992.
89. A. Intermittent Androgen Withdrawal Therapy for Advanced Prostate Cancer.
B. Hormonal Therapy: Basic Science. Cross Cancer Institute, Edmonton, Alberta, 1992.
90. Intermittent Androgen Withdrawal Therapy of Prostatic Carcinoma. University of Ottawa, Ottawa, Ontario, 1992.
91. Intermittent Androgen Suppression in the Treatment of Prostatic Carcinoma. University of Saskatoon, Saskatoon, Saskatchewan, 1992.
92. A. Biology and Control of Prostate Tumour Progression.
B. Intermittent Androgen Withdrawal Therapy for Prostate Cancer. Toronto-Bayview Regional Cancer Centre, Toronto, Ontario, 1992.
93. Hormonal Regulation of Prostate Growth. Symposium on Modern Trends in Benign Prostatic Hypertrophy Therapy, University of Washington School of Medicine, Seattle, Washington, USA, 1992.
94. Mechanisms of Tumor Progression After Androgen Ablation. Adjuvant Therapy of Urological Malignancies. Third Joint Symposium of the University of Vienna and the University of British Columbia, Vienna, Austria, 1993.
95. Hormone Manipulation: State of the Art. 37th Annual Cancer Symposium: Prostate Cancer, University of Saskatchewan, Saskatoon, Saskatchewan, 1993.
96. A. Mechanisms and Prevention of Tumor Progression.
B. Protocols for Clinical Trial of Intermittent Androgen Suppression. International Workshop on Intermittent Androgen Suppression in Prostate Cancer, Seattle, Washington, USA, 1993.
97. Hormone Manipulation: State of the Art. Mini-symposium on Prostate Cancer, Kelowna, British Columbia, 1993.
98. Prostate Cancer Biology and Novel Therapeutic Strategies. Symposium on Expanding Horizons in Prostate Cancer: Advances in the Management of Localized and Disseminated Disease, New York, New York, USA, 1993.
99. Intermittent Hormonal Therapy for Prostate Cancer. Satellite Meeting on Urologic Oncology Update, Las Croabas, Puerto Rico, 1993.
100. Biology of the Prostate Cell: Role of Hormones. Northeastern Section American Urological Association 45th Annual Meeting, San Juan, Puerto Rico, 1993.
101. A. Adverse Effects of Androgen Ablation on Stem Cells and Clusterin Synthesis in the Shionogi Carcinoma.
B. Intermittent Androgen Suppression in the Treatment of Prostate Cancer. The 5th Tokyo Symposium on Prostate Cancer: Fundamental Approach to Diagnosis and Treatment for Prostate Cancer and BPH, Tokyo, Japan, 1993.
102. Biology of Prostate Cell: Role of Hormones. University of Chiba, Chiba, Japan, 1993.
103. Biologic and Molecular Aspects of Intermittent Androgen Ablation. Samuel Waxman Foundation, Mount Sinai Medical Center, New York, New York, USA, 1994.
104. Novel Approach to Hormonal Therapy for Prostate Cancer. Division of Neoplastic Disease Grand Rounds, The Mount Sinai Medical Center, New York, New York, USA, 1994.
105. Prostate Cancer Biology and Novel Therapeutic Strategies. Division of Hematology and Oncology Grand Rounds, Wayne State University, Detroit, Michigan, USA, 1994.
106. Intermittent Androgen Suppression in the Treatment of Prostate Cancer. Institute of Oncology, University of New South Wales, Prince of Wales Hospital, Randwick, New South Wales, Australia, 1994.
107. A. Hormonal Therapy for Prostate Cancer.
B. Experimental Basis for Intermittent Androgen Suppression of Prostate Cancer. Urological Society of Australasia, 47th Annual Scientific Meeting, Broome, Western Australia, 1994.
108. Cell Death in the Shionogi Mammary Carcinoma: a Model for Treatment of Hormone Dependent Cancers. Tenth International Symposium on Cellular Endocrinology: Molecular and Cell Biology of Apoptosis in Development, Disease and Cancer, W. Alton Jones Cell Science Center, Inc., Lake Placid, New York, USA, 1994.
109. Adaptation and Tumor Progression After Androgen Ablation. Society for Basic Urologic Research Fall Symposium, Stanford, California, USA, 1994.
110. Nuevas Estrategias de Tratamiento en el Cancer de Prostata. XLV Congreso Nacional de Urologia, Cuernavaca, Morelos, Mexico, 1994.
111. Intermittent Androgen Blockade Therapy. Chemotherapy Foundation Symposium XII, Innovative Cancer Chemotherapy for Tomorrow, New York, New York, USA, 1994.
112. Biological Basis for Intermittent Androgen Suppression, a Novel Therapy for Prostate Cancer. Department of Urology Research Seminar, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA, 1994.
113. Intermittent Androgen Suppression in the Treatment of Prostate Cancer. Association des Urologues du Québec, XIXe Congrès Annuel, Québec City, Québec, 1994.
114. Mechanisms of Prostate Tumor Progression and Maintenance of Androgen Dependence. International Conference on Androgenic Hormones, Prostate Cancer and Benign Prostatic Hyperplasia, New Orleans, Louisiana, USA, 1995.
115. Calreticulin and Clusterin, Two Proteins With Possible Nuclear Functions that are Implicated in the Regulation of the Early and Late Stages of Apoptosis. New Orleans, Louisiana, USA, 1995.
116. The 3R's (Reductase, Receptor, Response Element) of Androgen Action: Basis of a Novel Therapy for Prostate Cancer. Japanese Urological Association 83rd Annual Meeting, Mukahari, Japan, 1995.
117. Intermittent Androgen Blockade. International Conference on Prostatic Carcinoma, Copenhagen, Denmark, 1995.
118. Update on Intermittent Androgen Suppression in the Treatment of Prostate Cancer. Urology symposium on "Androgenentzug und Lebensqualität", Vienna, Austria, 1995.
119. Intermittent Androgen Suppression- the Vancouver Experience. Mini-symposium on Intermittent Androgen Suppression, Victoria, British Columbia, 1995.
120. Neoadjuvant Hormonal Therapy for Prostate Cancer: The Canadian Experience. First International Conference on Neoadjuvant Hormonal Therapy for Prostate Cancer, Boston, Massachusetts, USA, 1995.
121. Intermittent Androgen Suppression for Prostate Cancer: Rationale and Clinical Experience. Northwestern University Robert H. Lurie Cancer Center, Chicago, Illinois, USA, 1996.
122. Intermittent Androgen Suppression for the Treatment of Prostate Cancer. Sydney, Australia, 1996.
123. A. Neoadjuvant Androgen Withdrawal Therapy Before Radical Prostatectomy: Three Months Versus Eight.
B. Control of Tumour Progression by Androgens.
C. Induction of Cell-Free In-vitro Transcription by Recombinant Androgen Receptor Peptides: a Tool for Studying Androgen Receptor Regulation and Tumour Progression.
D. Androgenic Regulation of PSA: Molecular, Translational and Clinical Aspects. Annual Meeting, New South Wales Section of the Urological Society of Australasia, Mt. Broughton, New South Wales, Australia, 1996.
124. Androgenic Regulation of PSA: Molecular, Translational and Clinical Aspects. Annual Meeting, Western Australian Section of the Urological Society of Australasia, Bunbury, Western Australia, 1996.
125. A. Intermittent Androgen Suppression for Prostate Cancer - Rationale and Clinical Experience.
B. Molecular Biology in Cancer of the Prostate. Northern Section of the Urological Society of Australasia, Maroochydore, Queensland, Australia, 1996.
126. Prepressor Function of Ap-1/C-Jun in the Androgenic Regulation of the PSA Gene. Flinders University of Southern Australia, Adelaid, South Australia, 1996.
127. Advances in the Treatment of Prostate Cancer: Intermittent Androgen Suppression and Long-Term Neoadjuvant Therapy. Urological Society of South Australia, Adelaide, South Australia, 1996.
128. Prostate Cancer - A Time for Optimism. Urological Society of Victoria, Melbourne, Victoria, Australia, 1996.
129. Repressor Function of Ap-1/c-Jun in the Androgenic Regulation of the PSA Gene. Aniology Centre, Prince of Wales Hospital, Randwick, New South Wales, Australia, 1996.
130. Biological Stepping Stones to a New Therapy for Prostate Cancer. Symposium on the Biology and Treatment of Prostate Cancer, Toronto Hospital, University of Toronto, Toronto, Ontario, 1996.
131. Intermittent Androgen Suppression for the Treatment of Prostate Cancer. Second International Forum on Prostate Cancer, The Prostate Cancer Charitable Trust, London, England, 1996.
132. The Use of LHRH Agonists in the Treatment of Prostate Cancer. Alza Corporation, Palo Alto, California, USA, 1997.
133. Intermittent Endocrine Treatment. International Symposium on Developments in Endocrine Management of Prostate Cancer, Berlin, Germany, 1997.
134. AP-1 and the Androgen Receptor: Factors in the Endocrine - Related Progression of Prostate Cancer. Gordon Research Conference on Hormonal Carcinogenesis, Tilton, New Hampshire, USA, 1997.
135. Intermittent Hormone Blockade in the Treatment of Prostate Cancer. Northwest Prostate Cancer Forum, University of Washington, Seattle, Washington, USA, 1997.
136. A. Prostate Cancer: Does Intermittent Androgen Suppression Have a Future?
B. Progression to Androgen Independence: A Wealth of New Information from Tumour Models of Prostate Cancer. 70th Reunion of the Department of Urology, Dalhousie University, Halifax, Nova Scotia, 1997.
137. Intermittent Androgen Suppression: A New Treatment Option for Prostate Cancer. Workshop in Prostatic Disease Management, Sunnybrook Medical Center, Toronto, Ontario, 1997.
138. Intermittent Androgen Suppression for Prostate Cancer: Recent Progress and Future Directions. Hamilton Regional Cancer Center, Hamilton, Ontario, 1997.
139. Prostatic Cancer: Intermittent Hormone Therapy. Antiandrogen Symposium, Istanbal, Turkey, 1997.
140. Prostate Cancer: Intermittent Hormone Therapy. Antiandrogen Symposium, Izmir, Turkey, 1997.
141. Prostate Cancer: Intermittent Hormone Therapy. Ankara, Turkey, 1997.
142. Intermittent Androgen Suppression for Prostate Cancer: Recent Progress and Future Directories. Bodo von Garrelts lecture, Karolinska Institute, Huddinge, Sweden, 1997.
143. Recent Advances in the Treatment of Prostatic Cancer. Prostate Cancer Support Group, Salt Spring Island, British Columbia, 1997.
144. Update on Hormonal Treatment of Prostatic Cancer. Schools of Specialization in Oncology, Urology, Endocrinology and Surgery, University of Perugia, Perugia, Italy, 1997.
145. Basic and Clinical Significance of Antiandrogen Intermittent Suppression. (Società Italiana di Andrologia) IV Giornate Andrologiche Italiane, University of Perguria, Perugia, Italy, 1997.
146. Intermittent Endocrine Therapy for Prostate Cancer: An Update. Society of Urologic Surgeons of Ontario, Toronto, Ontario, 1997.
147. Intermittent Endocrine Therapy for Prostate Cancer. Symposium on Progress and Controversies in Oncological Urology V (PAC10U V): An Update on Renal, Bladder and Prostate Cancer, Rotterdam, The Netherlands, 1998.
148. Intermittent Androgen Suppression for Prostate Cancer Patients Failing Radiation Therapy With a Rising PSA: Background and Recent Experience. Chemotherapy Foundation Symposium XVI, Innovative Cancer Therapy for Tomorrow, New York, New York, USA, 1998.
149. Canadian Prospective Trial on Intermittent Androgen Suppression for Prostate Cancer. 2nd International Meeting on Intermittent Androgen Ablation Therapy, Emmersdorf, Austria, 1999.
150. Prostate Cancer: Molecular Biology of Early Progression to Androgen Independence. University of Innsbruck, Innsbruck, Austria, 1999.
151. Intermittent Androgen Suppression for Prostate Cancer, Early Tumour Progression and Therapy With Anti-Sense bcl-2 Oligonucleotides. St Bartholomew's Hospital, London, England, 1999.
152. Canadian Prospective Trial of Intermittent Androgen Suppression for Men in Biomedical Relapse After Radiation of Locally Advanced Prostate Cancer. Fifth International Conference on Neoadjuvant Hormonal Therapy for Prostate Cancer, Boston, Massachusetts, USA, 2000.
153. Intermittent Androgen Deprivation. Carcinoma della Prostata, Convegno Internazionale, Genova, Italy, 2000.
154. Intermittent Androgen Suppression for prostate cancer and update. A) Prince of Wales Hospital, Sydney; B) Sir Charles Gairdner Hospital, Perth; C) Flinders University and Flinders Medical Centre, Adelaide, Australia, 2000.
155. Novel Targets for Cancer Treatment: From Bench to Bedside, Including Case Studies Highlighting Critical Issues in the Management of Hormone Dependent Cancers. Hormones and Cancer 2000, Port Douglas, Australia, 2000.
156. The Ups and Downs of Hormonal Therapy for Prostate Cancer. Sydney Urological Association, Sydney, Australia, 2000.
157. The Ups and Downs of the Hormonal Management of Prostate Cancer. Annual BC Cancer Agency Clinical Cancer Conference, Vancouver, British Columbia, 2000.
158. The Ups and Downs of the Hormonal Management of Prostate Cancer. Endocrinology Grand Rounds, Southwestern Medical School, Dallas, Texas, USA, 2001.
159. Intermittent Androgen Blockade in the Treatment of Prostate Cancer. 7th International Congress of Andrology, Montreal, Quebec, 2001.
160. The Ups and Downs of the Hormonal Management of Prostate Cancer. BC Urolological Society, Vancouver, British Columbia, 2001.
161. The Ups and Downs of the Hormonal Management of Prostate Cancer. Department of Urology, Northwestern University, Chicago, Illinois, USA, 2002.
162. Final Results of the Canadian Prospective Trial of Intermittent for Men in Biochemical Relapse After Radiotherapy for Locally Advanced Prostate Cancer. Intermittent Androgen Suppression Therapy Workshop with Professor Bruchovsky. Palace Building, Tokyo, Japan, 2004.
163. Experimental Basis for the Therapeutic Maintenance of Androgen Dependence in Prostate Cancer. 15th Prostate Cancer Workshop. National Cancer Center, Tokyo, Japan, 2004.
164.

Final Results of thePhase II Canadian Prospective Trial of Intermittent Androgen Supression for Men in Biochemical Relapse after Radiotherapy for Locally Advanced Prostate Cancer. First Meeting of International St udy of Intermittent Therapy for Cancer of the Prostate. Founders Hall, London , England , March 2005.

165.

Experimental Basis for the Therapeutic Main tenance of Androgen Dependence in Prostate Cancer. First Meeting of International St udy of Intermittent Therapy for Cancer of the Prostate. Founders Hall, London , England , March 2005.

166.

Intermittent Androgen Suppression: Rationale for an Innovative Approach to Androgen Deprivation Therapy. The Endocrine Society ( USA ) 90 th Annu Mtg, Symposium on Androgen and Potential Harms in the Prostate, San Francisco , USA , June 2008.

167.

Prostate Specific Antigen Doubling Time as a Continuously Changing Parameter During Intermittent Androgen Sup pre ssion Therapy for Prostate Cancer. Sixth International Symposium on Hormonal Oncogenesis. Tokyo , Japan , September 2010.

168.

Optimal Intermittent Androgen Sup pre ssion Based on a Mathematical Model. Sixth International Symposium on Hormonal Oncogenesis. Tokyo , Japan , September 2010.

169.

Mathematical Modelling of Prostate Cancer. International Workshop on Mathematical Modelling of Prostate Cancer. Santa Fe, New Mexico , USA , July 2010.

Research Funding

  1. Title: Vancouver Centre of Excellence in Prostate Cancer Research 
    Source: Health Canada 
    Amount to BCCA campus: $3,000,000; Full amount (both campuses): $10,000,000
    Applicants: M. Sadar (Director of BCCA campus); N. Bruchovsky (Member)
    L. Goldenberg (Director of VHHSC Campus)
    Term: 1999-2004 
    Major Goals: To coordinate the prostate related research initiatives of both the BC Cancer Agency (BCCA) and the Vancouver Hospital and Health Sciences Centre (VHHSC) such that a world’s leading prostate cancer research centre is created.
  2. Title: Inhibition of ligand-independent activation of the androgen receptor: a potential mechanism for blocking malignant progression of prostate cancer.
    Source: US Army, Department of Defense
    Amount: US $233,875
    Applicants: M. Sadar,(Principal Investigator), N. Bruchovsky (Coinvestigator) and P. Gout.
    Term: 1998-2001
  3. Title: PSA gene expression and regulation in androgen dependent and independent prostate cancer.
    Source: NIH, George M. O’Brien Research Center
    Amount: US $459,759
    Applicants: N. Bruchovsky (Principal Investigator), and M. Sadar
    Term: 1998-2003
  4. Title: A prospective study of intermittent androgen suppression in men with localized prostate cancer who have failed external beam irradiation.
    Source: Berlex Canada Inc.
    Amount: Cdn $1,000,000
    Applicants: N. Bruchovsky (Principal Investigator), L. Klotz, J. Crook, M. Gleave and L. Goldenberg
    Term: 1994-2001
  5. Endocrine Oncology Research supported by public donations amounting to Cdn $500,000 approximately.
  6. Title: Characterization of a new in vivo prostate tumor model that progresses to androgen-independence and its application in determining changes in gene expression.
    Source: US Army Medical Research Acquisition Activity
    Amount: US $222,195
    Applicants: M. Sadar (Principal Investigator), N. Bruchovsky (Coinvestigator)
    Term: 1999-2002

  7. Title: Intermittent androgen supression, analysis of clinical database and mathematical modelling
    Source: Liber Ero Foundation of Vancouver
    Amount: Cdn $500,000
    Applicants: N. Bruchovsky (Principal Investigator), J. Abersbach (Coinvestigator)
    Term: 1999-present

Reviewer - Journals, Committees

  • Canadian Journal of Biochemistry and Biology
  • Cancer Research
  • Journal of Clinical Endocrinology and Metabolism
  • Journal of Clinical Investigation
  • Journal of Urology
  • Journal of Steroid Biochemistry and Molecular Biology
  • Journal of Clinical Oncology
  • Medical Oncology Consultant, University of British Columbia Prostate Clinic
  • Editorial Board, The Prostate
  • Editorial Board, Endocrine Related Cancer
  • Research Management Committee, BC Cancer Agency
  • Research Executive Committee, BC Cancer Agency
  • Scientific Committee, Symposium on Progress and Controversies in Oncological Urology V (PACIOU V); Erasmus University Rotterdam, Rotterdam, The Netherlands
  • Scientific Committee, II nd International Meeting on Intermittent Androgen Suppression;
  • University of Vienna, Vienna, Austria
  • Committee on Management of Newly Diagnosed Metastatic Prostate Cancer, 2nd International Consultation on Prostate Cancer, World Health Organization/UICC, Paris, France
  • Principal Investigator and Coordinator, “Canadian Prospective Trial of Intermittent Androgen Suppression in the Treatment of Prostate Cancer.” 

Reviewer - Granting Agencies

  • Medical Research Council of Canada
  • National Cancer Institute of Canada
  • National Institutes of Health, U.S.A.
  • Netherlands Cancer Foundation
Home | Curriculum Vitae | Curriculum Vitae Abbreviated  | Biography | Lab Notes | Clinical Research